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ZUSAMMENFASSUNG 
Negativsymptomatik beeinträchtigt die meisten Patienten mit Schizophrenie im Verlauf 
der Erkrankung. Sie stellt einen wichtigen Prädiktor für Krankheitsverlauf sowie soziale und be-
rufliche Funktionsfähigkeit dar und ist bislang schwer positiv beeinflussbar. Um Negativsymp-
tomatik als verlässlichen primären Endpunkt in Studien zu etablieren, muss das Konstrukt klar 
operationalisiert und validiert werden. Aktuelle Faktorenanalysen ergeben meist zwei Faktoren: 
Expressions-Defizite und Amotivation. Es finden sich konzeptionelle Überschneidungen zwi-
schen Negativ- und depressiver Symptomatik. Zwei neu entwickelte Instrumente für Nega-
tivsymptomatik sind das Clinical Assessment Interview for Negative Symptoms (CAINS; Sub-
skalen Expression und Motivation und Freude) sowie der Motivation and Pleasure – Self Report 
(MAP-SR; aus der „Motivation und Freude“-Skala des CAINS entwickelt). Wir evaluierten um-
fassend ihre psychometrischen Eigenschaften und untersuchen, ob das CAINS das Konstrukt 
Negativsymptomatik und der MAP-SR die Subdomäne Amotivation zuverlässig misst. Ebenfalls 
wurde untersucht, ob CAINS und MAP-SR sowie zwei Depressions-Testverfahren Patienten mit 
Schizophrenie, Patienten mit Depression und Kontrollpersonen differenzieren können. Die zwei-
faktorielle Struktur des CAINS konnte bestätigt werden; wir fanden weiter insgesamt gute Vali-
dität und Reliabilität. Der MAP-SR ist geeignet, Anhedonie zu messen, scheint aber weniger gut 
einsetzbar für die Beurteilung von Motivation. Die Expressions-Subskala des CAINS differen-
zierte Personen mit Schizophrenie und Personen mit Depression. Für die selbstbewertete Nega-
tivsymptomatik zeigte sich kein signifikanter Unterschied zwischen den psychiatrisch erkrankten 
Stichproben. Expressive Defizite und moderate Depressionswerte deuten auf ein Negativsyn-
drom hin, wohingegen eine relativ unbeeinträchtigte Expression und viel selbstberichtete depres-
sive Symptomatik auf ein depressives Syndrom hinweisen. Es besteht Bedarf an validen und reli-
ablen Selbstbeurteilungs-Instrumenten für Negativsymptomatik. Das CAINS ist insgesamt gut 
geeignet, Negativsymptomatik reliabel zu beurteilen; seine beiden Unterskalen messen klar und 
weitgehend reliabel unterschiedliche Aspekte von Negativsymptomatik. 
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ABSTRACT 
Negative symptoms are prevalent in most patients with schizophrenia at some point of 
the illness. They constitute an important predictor of course of illness as well as social and 
occupational functioning and remain a major challenge with regard to treatment. For negative 
symptoms to become a reliable primary endpoint in studies, clear operationalization and 
construct validation is needed. Recent factor analyses mostly find the two factors diminished 
expression and amotivation. There is conceptual overlap between negative and depressive 
symptoms. Two recently developed instruments for negative symptoms are the Clinical 
Assessment Interview for Negative Symptoms (CAINS; subscales expression, and motivation 
and pleasure), as well as the Motivation and Pleasure – Self Report (MAP-SR, derived from the 
CAINS motivation and pleasure subscale). We comprehensively assessed their psychometric 
properties, inquiring whether the CAINS reliably measures the construct negative symptoms and 
the MAP-SR the subdomain amotivation. Further, we examined whether CAINS and MAP-SR 
and two depression ratings could differentiate subjects with schizophrenia, with depression and 
controls. We confirmed the CAINS’ two-factorial structure with the domains expressive deficits 
and amotivation and found overall good validity and reliability. The MAP-SR was found adequate 
to assess anhedonia but less suitable when assessing motivation. Particularly the CAINS’ 
expression subscale discriminated subjects with schizophrenia and subjects with MDE. The 
MAP-SR ratings showed no significant difference in self-rated negative symptoms between the 
psychiatric samples. Reduced expression and moderate levels of depression point to a negative 
syndrome, whereas relatively unimpaired expression and high scores of self-reported depressive 
symptoms indicate a depressive syndrome. There is need for valid and reliable self-rating 
instruments of negative symptoms. The CAINS is overall well suited to reliably assess negative 
symptoms; its two subscales clearly and mostly reliably measure distinct aspects of  negative 
symptoms.  
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meh (mɛ) excl 1 slang an expression of indifference or boredom ▪ adj 2 slang mediocre or boring 
(Butterfield, 2011) 
 
“I just don’t really feel like I used to” 
“I don’t know what to talk about with my friends” 
“He seems like a zombie – are you sure that’s not the medication?” 
“Yeah, group was OK – but I don’t think I want to go next week”  
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1. Negative Symptoms 
The following sections provide an overview of the concept negative symptoms: A brief 
placement in the context of the other symptom domains of psychotic disorders, a definition and 
demarcation (particularly from depression) of negative symptoms, an outline of the concept’s 
history, some information on their course, subtypes, impact and treatment, as well as recent 
research on their factorial structure and how this is represented in established and novel 
instruments assessing negative symptoms. 
1.1 Symptom Domains of Psychotic Disorders 
 Psychosis is featured in a wide range of diagnoses in the Fifth Edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-V) which can be referred to as psychotic 
disorders. The most notable of the non-affective psychoses are schizophrenia, schizoaffective 
disorder, schizophreniform disorder, delusional disorder, and brief psychotic disorder. Substance- 
or medication-induced psychotic disorder and psychotic disorder due to another medical 
condition are also psychotic disorders (Heckers et al., 2013). Sometimes the affective psychoses, 
i.e. bipolar disorder with psychotic features and major depressive disorder with psychotic 
features, are included as well (Van Os & Kapur, 2009). These psychotic disorders differ i.a. in 
duration of illness, extent of dysfunction, co-presence of depression or mania, level of 
bizarreness of delusions, associated substance use, and presence of a somatic disorder (e.g. Van 
Os & Kapur, 2009). The A criteria for the diagnosis of schizophrenia consist of five 
psychopathological domains, namely hallucinations, delusions, disorganized speech, abnormal 
psychomotor behavior and negative symptoms. Symptom load can vary markedly within patients 
sharing the same diagnosis and the extent of severity of the symptom domains is important for 
differential diagnosis. Furthermore, there is evidence for shared genetic causes in the different 
psychotic disorders, as well as evidence for a continuum of “normal” thought to clinical 
psychosis (e.g. Allardyce, Suppes, & van Os, 2007). Thus, for quite some time researchers call 
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upon routinely including dimensional assessments of symptom domains to complement the 
standard categorical classifications; they argue this helps to more accurately determine prognosis 
and suitable treatments (Allardyce et al., 2007; Barch et al., 2013; Heckers et al., 2013; Van Os & 
Kapur, 2009). 
 According to Van Os and Kapur (2009), analysis of the psychopathology of psychotic 
disorders suggests that symptoms can be clustered into five main domains: 1) psychosis (i.e. 
delusions and hallucinations; the positive symptom domain), 2) changes in drive and volition (e.g. 
lack of motivation, reduction of spontaneous speech, and social withdrawal; the negative-
symptom domain), 3) changes in neurocognition (deficits in memory, attention, and executive 
functioning; the cognitive symptom domain), and affective dysregulation with 4) depression and 
5) mania. Aiming to merge this finding with the DSM-5’s diagnostic criteria, Barch et al. (2013) 
argue for the assessment of eight domains, namely the above-mentioned five diagnostic A criteria 
for schizophrenia (i.e. hallucinations, delusions, disorganized speech, abnormal psychomotor 
behavior, negative symptoms) as well as depression, mania, and impaired cognition. They make 
the case for the inclusion of delusion and hallucinations as separate domains, noting that while 
both are signs of impaired reality testing, a) some of the psychotic disorders feature only 
delusions or hallucinations and b) since some treatments (e.g. cognitive behavioral therapy) target 
hallucinations and delusions differently, clinicians should be able to assess them separately. 
Conversely, for the negative symptom domain, Barch et al. (2013) argue against the division into 
the two subdomains reduced expression and avolition (which will be elaborated on in depth in section 
1.6). They cite high correlations between the dimensions, current lack of effective treatment and 
the desire not to include too many dimensions. Concerning the three dimensions not featured in 
the A criteria for schizophrenia of the DSM-V, Barch et al. (2013) justify their inclusion thusly: 
For mania and depression, firstly, they point out evidence for schizoaffective disorder not being 
in an entirely distinct category separate from schizophrenia. Secondly, in patients with 
schizophrenia, the severity of mood symptoms is thought noteworthy with regard to prognosis 
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and outcome. Furthermore, they cite emerging evidence that treatment should specifically target 
affect. They did not consider cognition a differential diagnostic marker for schizophrenia and 
thus decided against including cognitive dysfunction in the A criteria, or the criteria for other 
psychotic disorders. However, they stress that a significant proportion of patients with psychotic 
disorders experience cognitive impairment, that there is a connection between cognitive function 
and functional status, and that cognitive deficits need specific treatments. 
The DSM-5 includes the dimensional assessments of psychosis on those eight domains of 
psychopathology in section 3 (referred to for more study); see figure 1-1. The dimensions are to 
be rated for their current severity (most severe past month) on a five-point scale from 0 (not 
present) to 4 (present and severe). Scores equal to or higher than 2 imply that a criterion A diagnostic 
indicator for schizophrenia is fulfilled. 
 
Notes. 0 = not present; 1 = equivocal; 2 = present, but mild; 3 = present and moderate; 4 = present and severe. 
Figure 1-1. Dimensional assessment of psychosis according to DSM-V. 
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1.2 What Are Negative Symptoms? 
 Andreasen (1982) described five domains of negative symptoms that still stand to this day 
(Ahmed, Strauss, Fernandez-Egea, & Kirkpatrick, 2019; Millan, Fone, Steckler, & Horan, 2014). 
Blunted affect (or affective flattening or blunted expression) is characterized by lower intensity and 
smaller range of verbal and nonverbal expression of emotion including intonation (prosody), 
facial expression, hand-gestures and body movements. Alogia (or poverty of speech) is marked by 
decreased quantity of speech, reduced spontaneous speech and loss of conversational fluency 
(poverty of content of speech now is usually classed with disorganization (Millan et al., 2014)). 
Social withdrawal (or asociality) manifests itself by reduced interest in, motivation for, and joy in 
social interactions and close relationships. Avolition (or amotivation or loss of volition) is the lack 
of drive and motivation to begin and maintain goal-directed behavior, especially when requiring 
cognitive or physical effort and significant organization. This is further related to apathy and lack 
of energy. Lastly, anhedonia is characterized by the inability to experience joy and pleasure. With 
regard to anhedonia, anticipatory pleasure (i.e. looking forward to a reward, recreational or other 
pleasurable experience; “wanting”) was found to be impaired more strongly than consummatory 
pleasure – the appreciation (“liking”) of the experience itself (Gard, Kring, Gard, Horan, & 
Green, 2007; Millan et al., 2014). This points to a motivational deficit as opposed to a deficit of 
emotion perception (Foussias & Remington, 2010). Those five rationally derived symptom 
domains are strongly represented in assessment instruments. However, clinical studies rarely 
assess them separately (Kirkpatrick et al., 2006). 
As there are different pathways leading to negative symptoms, the term secondary negative 
symptoms was introduced and highlights an important distinction (Carpenter, Heinrichs, & 
Wagman, 1988; Kirschner, Aleman, & Kaiser, 2017): While primary negative symptoms are caused 
directly by the disease of schizophrenia, secondary negative symptoms are induced by other 
factors. Kirschner et al. (2017) summarize that increased scores on negative symptom scales can 
be due to the following causes: 1) depression that includes i.a. anhedonia (e.g. Lako, Bruggeman, 
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et al., 2012), 2) positive symptoms that can lead to social withdrawal (e.g. Kelley, van Kammen, & 
Allen, 1999; Tandon et al., 2000), 3) side effects of medication that include emotional blunting 
(Kelley et al., 1999; Prosser et al., 1987), 4) substance use that can cause amotivation (e.g. Rovai 
et al., 2013), and 5) environmental conditions like social deprivation that can lead to avolition and 
social withdrawal (Kasanova, Oorschot, & Myin-Germeys, 2018; Oshima, Mino, & Inomata, 
2005). 
For quite some time, cognitive symptoms were thought of as part of the negative 
symptom domain. There are parallels with regard to prevalence, course of illness, role in 
prognosis, and correlation with functional impairment (e.g. Foussias & Remington, 2010; Harvey, 
Koren, Reichenberg, & Bowie, 2006). Furthermore, low-to-moderate correlations for negative 
symptoms and cognitive deficits were found (0.1 to 0.3; Dominguez Mde, Viechtbauer, Simons, 
van Os, & Krabbendam (2009)). However, some of this overlap could be explained by the 
sometimes imprecise definition of the negative symptoms domain. For example, “difficulty in 
abstract thinking” and “stereotyped thinking” feature in the Negative Scale of the Positive and 
Negative Symptoms Scale (PANSS, Kay, Fiszbein, & Opler (1987)), and there is an attention 
subdomain in the Scale for Assessment of Negative Symptoms (SANS, Andreasen (1989)). This 
can blur the line to the cognitive symptoms domain (Harvey, Green, Bowie, & Loebel, 2006). In 
a longitudinal study, Bell and Mishara (2006) found no link between change in negative 
symptoms and neurocognition. The authors conclude that while the symptoms co-occur, neither 
causes the other and they do not change at the same time, and thus, they represent semi-
autonomous disease processes. Harvey, Koren, et al. (2006) reinforce this notion by scrutinizing 
four theoretical models by reviewing the available evidence, including recent path analysis studies. 
They conclude that negative and cognitive symptoms are separable, if not conceptually 
independent, domains of schizophrenia. As of now, cognitive symptoms are not thought of as 
part of the negative symptom domain anymore (e.g. Marder & Galderisi, 2017). 
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1.3 Distinction from Depression 
Negative and depressive symptoms aren’t trivial to differentiate, as there is considerable 
conceptual overlap. The main symptoms of depression – loss of interest, anhedonia, and reduced 
energy – can also be found in subdomains of negative symptoms: amotivation, avolition, and – to 
a certain extent – social withdrawal. However, emotional expression (i.e. speech, gestures and 
facial expressions) is often reduced in patients with schizophrenia compared to healthy controls 
and subjects with depression, with the latter nevertheless also showing expressional deficits 
(Berenbaum & Oltmanns, 1992; Gaebel & Wölwer, 2004; Riehle, Mehl, & Lincoln, 2018; 
Trémeau et al., 2005). Despite present affective blunting, patients with schizophrenia often report 
unimpaired subjective experiences of pleasure (e.g. Kring & Moran, 2008), whereas low, 
depressed mood is a main symptom of depression. Recent conceptualizations of anhedonia 
emphasize the importance of the (complex) reward system. Any reward system deficit (e.g. 
motivation, anticipatory pleasure, (cognitive) disorganization) can hinder the individual from 
generating pleasurable experiences and could then present as (secondary) consummatory 
anhedonia (Lambert et al., 2018). There are findings indicating that patients with depression 
experience consummatory and anticipatory anhedonia, whereas patients with schizophrenia 
mainly show a deficit in anticipatory pleasure (Gard et al., 2007; Lambert et al., 2018; Wu et al., 
2017). The emergence of anticipatory pleasure is more complex than the experience of 
consummatory pleasure and hints at motivational deficits in schizophrenia as opposed to deficits 
in experiencing emotions (Foussias & Remington, 2010). 
When taking the phase of illness into account, depressive symptoms don’t seem to 
systematically correlate with negative symptoms. In patients with schizophrenia, Peralta, Cuesta, 
Martinez-Larrea, and Serrano (2000) found no relationship with negative symptoms on admission 
(0.01) and a large correlation (0.51) on discharge from psychiatric hospitals. Others found no 
significant (S.-W. Kim et al., 2006; Wallwork, Fortgang, Hashimoto, Weinberger, & Dickinson, 
2012) or a significant but moderate relationship (Schrank, Amering, Hay, Weber, & Sibitz, 2014) 
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of negative and depressive symptoms in patients with schizophrenia. Nevertheless, comorbidity 
rates are high for schizophrenia and unipolar depression across stage and state of illness: In an 
acute psychotic episode up to 60% of patients experience a comorbid major depressive episode 
(MDE); post-psychosis 20% of chronic and 50% of first-episode patients have moderate to 
severe MDE (Upthegrove, Marwaha, & Birchwood, 2017). Longitudinally, up to 80% of patients 
with schizophrenia experience an episode of major depression (Upthegrove et al., 2010). 
Birchwood, Iqbal, and Upthegrove (2005) propose three pathways to depression in 
schizophrenia: 1) depression as intrinsic part of psychosis, 2) depression as a psychological 
reaction to the diagnosis and its implications for i.a. social status, and 3) depression as result of 
biographical childhood trauma. Childhood trauma now is a well-established risk factor for 
schizophrenia (e.g. Popovic et al., 2019). Concerning the second pathway, Upthegrove et al. 
(2017) summarize several findings indicating that the meaning and significance of the psychotic 
experience to the patient, and the impact of the diagnosis on social status influences the 
development of depression. Research on the first pathway is still in its early stages. 
Of the utmost clinical relevance is the fact that depression is the most important indicator 
for completed suicide in patients with schizophrenia (Dutta, Murray, Allardyce, Jones, & Boydell, 
2011). Since both the treatment of depression in schizophrenia and of negative symptoms 
remains inadequate (e.g. Fusar-Poli et al., 2015; Lako, Taxis, et al., 2012), it seems of particular 
importance to reliably delineate negative and depressive symptoms. 
For schizophrenia patients, we found some evidence for overlap when measuring the two 
symptom domains (Engel, Fritzsche, & Lincoln, 2014; Engel & Lincoln, 2016; Hartmann, 
Fritzsche, & Lincoln, 2013; Kring, Gur, Blanchard, Horan, & Reise, 2013; Llerena et al., 2013; 
Park et al., 2012). Bottlender et al. (2003) found that negative symptoms (measured with the 
SANS) were significantly associated with depressive symptoms in MDE patients but not in 
patients with schizophrenia. This could be due to the SANS’ item content that encompasses a lot 
of symptoms also germane to the depressive domain (e.g. affective nonresponsivity, poverty of 
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content of speech, increased latency of response) and symptoms that are not thought to be 
specific for negative symptoms anymore, i.e. attention/cognitive symptoms (e.g. Marder & 
Galderisi, 2017). They found persisting negative symptoms to be indicative for schizophrenia and 
not MDE. 
1.4 Historical Outline of the Concept 
Early on, what we now call negative symptoms were considered a central and severely 
impairing aspect of schizophrenia. The first modern descriptions of the mental illness that would 
later be called schizophrenia emerged in mid 19th century Europe. In 1860, Bénédict Augustin 
Morel described démence précoce, in 1863 Karl Ludwig Kahlbaum characterized the catatonic 
syndrome, in 1871 Ewald Hecker wrote of hebephrenia, and in 1906 Thomas Smith Clouston 
described adolescent insanity (e.g. Jablensky, 2010). In 1896, Emil Kraepelin, however, was the first 
to summarize the different clinical pictures and to propose the distinct disease dementia praecox; he 
emphasized similar courses of illness leading to severe cognitive and behavioral impairment (e.g. 
Jablensky, 2010; Zec, 1995). Describing nine clinical forms and acknowledging the varied clinical 
pictures, he proposed two fundamental groups of disorders in patients with dementia praecox: 
disorders of volition and psychic disintegration (Kraepelin, 1913). According to Kraepelin (1913), the 
disorders of volition manifest in emotional dullness, failure of mental activities, loss of mastery 
over volition, loss of endeavor, and loss of ability for independent action, most of which 
correspond to the modern concept of negative symptoms. Eugen Bleuler (1911) coined the term 
schizophrenia and expanded Kraepelin’s disorders with illnesses with less grim outcomes. He 
emphasized schizophrenia being a group of diseases and distinguished basic (obligatory) and 
accessory (supplementary) symptoms. Delusions and hallucinations were categorized as accessory 
symptoms, while basic symptoms were thought to characterize the illness and comprised deficits 
in associations, ambivalence, affective incongruence as well as withdrawal from reality, again 
showing similarities to present-time negative symptoms (e.g. Jablensky, 2010). 
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In the 1950s and 60s antipsychotic medication made possible a relatively satisfactory 
pharmacological treatment of positive symptoms of psychosis (Lehmann & Ban, 1997; Meyer & 
Simpson, 1997; Shen, 1999). This seemed to result in a stronger focus on this aspect of 
schizophrenia with regard to diagnosis, research and treatment (Foussias & Remington, 2010; 
Tandon et al., 2013). Maybe Kurt Schneider’s first-rank symptoms already foreshadowed this 
development in 1950. He ascribed a decisive weight for the diagnosis of schizophrenia to 
auditory hallucinations (of voices), thought withdrawal and other interference with thought, 
thought broadcasting, somatic hallucinations, delusional perception, as well as the experience of 
impulses and feelings as caused by external agents (e.g. Jablensky, 2010; Soares-Weiser et al., 
2015). They feature heavily in the current major classification systems DSM and the International 
Statistical Classification of Diseases and Related Health Problems (ICD), but may not be as 
decisive as formerly thought: less than 10% of cases were diagnosed only by first-rank symptoms 
in a field trial of the DSM-IV (Bertelsen, 2002; Flaum et al., 1998). 
Berrios (1985) argues that the general differentiation between positive and negative 
symptoms originated with John Russel Reynolds in 1858. When describing epilepsy, Reynolds 
distinguished negative symptoms – the negation of vital properties, citing paralysis and anesthesia 
– and positive symptoms – the excess or alteration of vital properties, e.g. spasms, pain, and 
convulsions. John Hughlings Jackson used the positive-negative distinction from 1875 on with 
regard to “insanity”, postulating that negative symptoms or the loss of higher-order nervous 
functioning leads to excessive lower-order functioning, i.e. positive symptoms (Berrios, 1985). In 
the 1930s and 40s – and not widely known – the French psychiatrist Gaëtan Gatian de 
Clérambault applied the positive-negative distinction to psychosis, differentiating interloping 
phenomena (i.e. positive symptoms) such as hallucinations and delusions from inhibitory 
phenomena (i.e. negative symptoms), in his case thought withdrawal, perplexity, and attentional 
impairment. Diverging from Reynolds and closer to the current view, he saw no interdependence 
of the symptom domains (Berrios, 1985, 1991). 
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With regard to schizophrenia, it took until the 1970s and early 1980s for the terms 
positive and negative symptoms to come into broader use, replacing the terms defect symptoms and 
productive symptoms (i.a. Berrios, 1985; Jablensky, 2010; Mackay & Crow, 1980; Wing, 1978). In 
1980, Crow proposed two subtypes of schizophrenia with type I characterized by positive 
symptoms and type II marked by negative symptoms. Andreasen and Olsen (1982) suggested 
three subtypes: positive, negative, and mixed schizophrenia. They further proposed criteria and rating 
scales for positive (Scale for the Assessment of Positive Symptoms (SAPS)) and negative (SANS) 
schizophrenia (Jablensky, 2010). Further to that, Carpenter et al. (1988) identified a subtype of 
schizophrenia, the deficit syndrome, characterized by enduring primary negative symptoms 
reminiscent of Kraepelin’s dementia praecox (Jablensky, 2010). The subtypes will be described in 
more detail in the next section. The more precise definitions of negative symptoms mentioned in 
section 1.2 were formulated during this period as well (e.g. Andreasen, 1982). 
With regard to the impact of and the as of yet unsatisfying treatment options for negative 
symptoms (see section 1.5), in 2005, the National Institute of Mental Health Consensus 
Development Conference on Negative Symptoms (Kirkpatrick, Fenton, Carpenter, & Marder, 
2006) reviewed the concept negative symptoms and called for intensified research efforts 
concerning the definition, assessment and treatment of the negative symptom complex. The 
effects and results of this will be further elaborated in sections 1.6 and 1.8. 
1.5 Prevalence, Subtypes, Course, and Impact of Negative Symptoms 
The initial diagnosis of schizophrenia is usually established with the first psychotic 
episode, i.e. above-threshold positive symptoms. This first psychotic episode typically happens in 
late adolescence and early adulthood (for women there is a second peak after 40); early-onset (< 
18 years) schizophrenia affects less than one in five patients (Millan et al., 2014; Ochoa, Usall, 
Cobo, Labad, & Kulkarni, 2012; Schimmelmann, Conus, Cotton, McGorry, & Lambert, 2007). 
Only approximately 10-15% of patients recover; there usually is a fluctuating course with 
CHAPTER 1: GENERAL INTRODUCTION 
 
12 
intermittent psychotic crises (e.g. Millan et al., 2014). While we can differentiate secondary and 
primary negative symptoms by their cause, the course and extent of negative symptoms makes 
possible further distinctions: Tandon et al. (2000) propose different components affecting 
patients in different phases of the illness: 1) a premorbid component, present in the prodromal 
phase, 2) a phasic component during psychotic episodes, and 3) a deteriorative component, 
persisting over time. 
Addington et al. (2015) assessed prodromal symptoms of 764 subjects at clinical high risk 
for psychosis and found at least one negative symptom in 82% and three or more in 44% of 
participants. Thus, many high-risk subjects experience relevant negative symptoms. Carrión et al. 
(2016) found negative symptoms to predate attenuated positive symptoms by approximately 
twelve months. The onset of negative symptoms in the prodromal phase is associated with social 
withdrawal and impaired social cognition, neurocognitive and mood deficits, and functional 
decline (e.g. Lyne et al., 2018; Millan et al., 2014). The acute phase component of negative 
symptoms is marked by decreased expression, further social withdrawal and functional 
impairment; in this phase, a substantial part of negative symptoms could be secondary negative 
symptoms (Lyne et al., 2018). Patel et al. (2015) analyzed routine clinical care records of 7 678 
patients in the acute psychotic phase and found at least two negative symptoms in 41% of 
patients. Similar rates (40 to 58%) were found in previous studies (Bobes, Arango, Garcia-Garcia, 
& Rejas, 2010; C. I. Cohen, Natarajan, Araujo, & Solanki, 2013; Jäger et al., 2009). 
The worsening, persisting component seems to be reflected in some of the proposed 
subtypes of schizophrenia first mentioned in section 1.4, namely Crow’s (1980) type II syndrome, 
Andreasen and Olsen’s (1982) negative schizophrenia, and Carpenter and colleagues’ (1988) 
deficit syndrome. Type II syndrome is marked by negative symptoms (here: affective flattening 
and poverty of speech) and equivalent to the defect state, type I syndrome is characterized by 
positive symptoms (here: delusions, hallucinations, and thought disorder) and corresponding to 
acute schizophrenia. Crow (1980) considers these two subtypes not mutually exclusive. He 
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thought type I symptoms to be associated with dopaminergic dysfunction, possibly treatable with 
antipsychotics, and reversible. Type II is possibly associated with intellectual impairment and 
brain abnormalities, may be enduring, and predict poor outcome (Crow, 1980). According to 
Andreasen and Olsen (1982) prominent delusions, hallucinations, positive formal thought 
disorder, and persistently bizarre behavior mark positive schizophrenia, while negative 
schizophrenia is characterized by affective flattening, alogia, avolition, anhedonia, and attentional 
impairment. In mixed schizophrenia, either both negative and positive symptoms or neither are 
dominant. 
The deficit syndrome of Carpenter et al. (1988) seems to have been taken up and 
expanded on the most by further researchers. It has been defined as the presence of at least two 
of six negative symptoms at a clinically significant level (restricted affect, diminished emotional 
range, poverty of speech, curbing of interest, diminished sense of purpose, and/or diminished 
social drive) that have been present for twelve months (including periods of clinical stability 
including chronic psychotic states) and are not secondary to factors other than the disease 
process (i.e. not secondary negative symptoms) in patients meeting the diagnostic criteria for 
schizophrenia (Wagman, Heinrichs, & Carpenter, 1987). In a review, Kirkpatrick, Buchanan, 
Ross, and Carpenter (2001) suggest that deficit schizophrenia constitutes a disease separate from 
non-deficit forms. Kirkpatrick, Mucci, and Galderisi (2017) argue that there may be more white 
matter changes in deficit compared to non-deficit patients and they may relate to problems in 
early brain migration; the two groups also seem to differ on metabolic measures prior to 
antipsychotic medication. Jablensky (2010) summarized research finding no difference of age at 
onset and duration of illness when comparing deficit syndrome and non-deficit syndrome 
patients. Furthermore, he cites a prevalence of the deficit syndrome of 16.5% in unselected 
epidemiological samples of patients with schizophrenia and 25-30% in samples of patients with 
chronic schizophrenia. 
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In 2005, the National Institute of Mental Health Consensus Development Conference on 
Negative Symptoms aimed to reduce the heterogeneity of negative symptoms by developing 
criteria easily applicable in the context of clinical trials (Kirkpatrick et al., 2006). They introduced 
the concept of persistent negative symptoms which are defined more broadly than the deficit 
syndrome. Persistent negative symptoms are negative symptoms of schizophrenia that 1) are 
either primary to the illness or are secondary, but unresponsive to usual treatments, 2) interfere 
with everyday functioning, 3) persist in clinically stable phases, and 4) represent an unmet 
therapeutic need (Kirkpatrick et al., 2006). The concrete criteria are an at least moderate severity 
of negative symptoms for an extended period of time (usually six months), a defined threshold 
level of positive symptoms, and no (or a low level of) depressive symptoms and extrapyramidal 
symptoms; all defined on an accepted and validated rating scale (Buchanan, 2007). For a 
retrospective study of 660 psychiatric inpatients, Buchanan (2007) reports a prevalence of 
persistent negative symptoms of 25.7% in subjects with schizophrenia, 8.1% for schizoaffective 
disorder, 2.3% for mood disorders, and 15.6% for psychotic disorders not otherwise specified. 
Galderisi, Mucci, et al. (2013) found persistent negative symptoms not confounded by depression 
or extrapyramidal symptoms in 6.7% of a sample of 345 first-episode patients with 
schizophrenia. 
Data on the long-term course of negative symptoms is conflicting: A meta-analysis 
including 89 samples from 41 studies (n = 5944) mostly found improvement in negative 
symptoms in schizophrenia outpatients with effect sizes ranging from small to large; this was 
found for treatments as well as placebo (Savill, Banks, Khanom, & Priebe, 2015). However, 
possible moderators of improvement (e.g. changes in causes for secondary negative symptoms) 
were not analyzed in those studies (Galderisi, Mucci, Buchanan, & Arango, 2018). In a twenty-
year follow-up study of 50 first-episode schizophrenia patients Kalisz and Cechnicki (2016) 
reported low rates of persistent negative symptoms and deficit syndrome after one year (4 and 
6%, respectively), and no symptoms after twelve and twenty years. Negative symptoms were 
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present in 20% of the initially assessed patients after one year, and in 40% of that subsample in 
the follow-ups. However, Austin et al. (2015) assessed 496 patients with first-episode psychosis 
across ten years and found a continuous course of negative symptoms for 27% and a relapsing 
course for 26% of patients. Overall, negative symptoms showed less variation than positive 
symptoms. Furthermore, for the deficit syndrome, several studies report a long-term stability of 
67 to 83% (Amador et al., 1999; Galderisi, Bucci, et al., 2013; Strauss, Harrow, Grossman, & 
Rosen, 2010). 
Very early on, clinicians and researchers recognized that poor outcomes were associated 
with negative symptoms. Negative symptoms are consistently among the most important 
predictors for course of illness, social and occupational functioning as well as quality of life – all 
are worse with a greater extent of negative symptoms (e.g. Kaiser et al., 2017; Marder & 
Galderisi, 2017; Novick, Haro, Suarez, Vieta, & Naber, 2009; Rabinowitz et al., 2012). This 
especially holds true for patients with deficit syndrome (e.g. Kirkpatrick & Galderisi, 2008). 
Despite their importance particularly in the long term, as of yet negative symptoms are 
difficult to treat both with medication and non-biological treatments (Arango, Garibaldi, & 
Marder, 2013; Lehman et al., 2004; Leucht, Arbter, Engel, Kissling, & Davis, 2009; Singh, Singh, 
Kar, & Chan, 2010; Turner, van der Gaag, Karyotaki, & Cuijpers, 2014; Velthorst et al., 2014). A 
recent meta-analysis found no clinically effective interventions, despite statistically significant 
results (Fusar-Poli et al., 2015). However, there are promising non-biological interventions that 
could be optimized and should be researched on further, namely cognitive-behavioral therapy, 
skills-based training (particularly social skills training (see also Turner et al., 2018), exercise, and 
music treatments (Lutgens, Gariepy, & Malla, 2017). A more precise definition of negative 
symptoms and sophisticated measurement instruments seem essential for progress in this area of 
research. 
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1.6 Factorial Structure of Negative Symptoms 
The renewed interest in negative symptoms evident in the National Institute of Mental 
Health Consensus Development Conference on Negative Symptoms (Kirkpatrick et al., 2006) 
has lead to several inquiries on the structure of the construct. Factor analyses of different 
instruments measuring negative symptoms have found two- and three-factor models; there is 
sound evidence for overlap as well as distinction of the (rationally derived) subdomains affective 
blunting, alogia, social withdrawal, avolition, and anhedonia (e.g. Blanchard & Cohen, 2006; 
Galderisi et al., 2018). For the two classic instruments assessing negative symptoms – the SANS 
and the Schedule for the Deficit Syndrome (SDS, Kirkpatrick, Buchanan, McKenny, Alphs, and 
Carpenter (1989)) – two factors loading on the theoretically derived five subdomains were found 
with some consistency (Keefe et al., 1992; Kimhy, Yale, Goetz, McFarr, & Malaspina, 2006; 
Nakaya & Ohmori, 2008; Peralta & Cuesta, 1999; Strauss et al., 2013). One of the factors covers 
expressive deficits and consists of blunted affect and alogia, the other, amotivation, is comprised of 
items assessing avolition, anhedonia, and social withdrawal and points to issues of involvement 
with the surrounding environment (e.g. Blanchard & Cohen, 2006; Foussias & Remington, 2010; 
Kirkpatrick, 2014). These two factors were also found when analyzing the more global psychosis 
assessment instruments PANSS and Brief Psychiatric Rating Scale (BPRS, Overall and Gorham 
(1962)) on their items measuring negative symptoms (e.g. Blanchard & Cohen, 2006; Liemburg et 
al., 2013). Further, diminished expression and amotivation have been found as independent 
factors in first-episode and chronic patients, as well as in patients with deficit syndrome (e.g. 
Foussias, Agid, Fervaha, & Remington, 2014; Messinger et al., 2011). When analyzed, 
inappropriate affect, poverty of content of speech, and attention deficits – all symptoms formerly 
thought of as part of the negative symptom domain – were found to load on a third factor that 
seems to be more closely related to disorganized symptoms of schizophrenia (e.g. Foussias & 
Remington, 2010; Marder & Galderisi, 2017). 
CHAPTER 1: GENERAL INTRODUCTION 
 
17 
As of yet, the two-factorial structure of negative symptoms has become scientific 
consensus (Galderisi et al., 2018) and has been taken up in the DSM-V as diminished emotional 
expression and avolition. Testing a more sophisticated structure, a very recent factorial analysis of 
Ahmed et al. (2018) of a new instrument measuring negative symptoms, the Brief Negative 
Symptom Scale (BNSS, Kirkpatrick et al. (2011)), found two second-order factors: expression 
and amotivation, and five first-order factors: blunted affect, alogia, anhedonia, avolition, and 
asociality. Thus, despite major advancement in recent years, a final conclusion on the exact 
structure of negative symptoms has not yet been achieved. Nevertheless, diminished expression 
and amotivation feature dominantly in each of the models that are currently investigated. 
Foussias and Remington (2010) summarize findings on the interrelatedness of the two 
domains citing inter-factor correlations of 0.47 to 0.57 as well as moderate interrelationships of 
SANS items across the two factors. They conclude that the two subdomains may have common 
as well as distinct underlying processes. Kaiser et al. (2017) find that models of amotivation are 
pointing to dysfunctions of the reward system and aspects of goal directed behavior and judge 
models of expressive deficits to still be in an early phase of development. Galderisi et al. (2018) 
hypothesize two underlying mechanisms/circuits for amotivation: 1) of the motivational value 
system leading to impaired anticipatory pleasure, valuation of action and stimuli, and instrumental 
learning, and 2) of the motivational salience system resulting in deficits with regard to orientation 
towards salient stimuli, cognitive activation, and general motivation. They argue that those two 
mechanisms should profit from different treatment approaches, calling for enhancement of 
instrumental learning and provision of external rewards in the case of dysfunction in the 
motivational salience circuit and for pharmacological and psychosocial treatments increasing 
salience of stimuli and activating cognition for a dysfunctional motivational value circuit. Marder 
and Galderisi (2017) cite contradictory findings for the link of a) avolition with global impairment 
in decision making and executive functioning, and b) social withdrawal with social cognition 
deficits, calling for further research. Expressive deficits seem to be associated with 
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neurocognitive impairment as well as social cognition deficits (Marder & Galderisi, 2017). 
Deficits in expression are more persistent (e.g. Kelley, Haas, & van Kammen, 2008), while 
motivational deficits correlate more strongly with functional outcome (e.g. Fervaha, Foussias, 
Agid, & Remington, 2014). Concerning psychotherapeutic interventions, there is preliminary 
evidence for different outcomes for the two domains: Amotivation seems to improve more with 
CBT and social skills training, while verbal and nonverbal expression profits from nonverbal 
treatments like body-oriented psychotherapy (e.g. Kaiser et al., 2017; Riehle, Pillny, & Lincoln, 
2017). 
Overall, these findings support negative symptoms as a multidimensional construct. Thus, 
early on there was a push for a broader assessment of the different domains to aid research on 
their possibly different etiologies, impact and treatment needs (Blanchard & Cohen, 2006). This 
lead to the development of new measurement instruments for negative symptoms, which were 
constructed with the empirically established factorial structure in mind (see section 1.8). 
1.7 Established Instruments for the Assessment of Negative Symptoms 
Until recently, negative symptoms were mostly assessed using the SANS (Andreasen, 
1989) and PANSS (Kay et al., 1987), which will be the focus of the first part of this section (e.g. 
Galderisi et al., 2018). The SANS consists of 20 items (excluding global items) belonging to five 
subscales: affective flattening, alogia, avolition/apathy, anhedonia/asociality, and inattention. The PANSS’ 
Negative Scale has seven items assessing blunted affect, emotional withdrawal, poor rapport, 
passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of 
conversation, and stereotyped thinking (see also Blanchard & Cohen, 2006). While both scales 
deserve praise for prominently featuring negative symptoms and making structured research on 
them possible in the first place, recently, there has been criticism as they don’t seem to reflect the 
current state of the art (e.g. Blanchard, Kring, Horan, & Gur, 2011; Marder & Galderisi, 2017; 
Millan et al., 2014). First of all, both scales assess cognitive symptoms, which are not thought of 
as part of the negative syndrome anymore. The PANSS does not cover all five subdomains of 
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negative symptoms since it doesn’t assess anhedonia. Then, the scales focus to a relatively high 
degree on observable behavior during the interviews and report of functional deficits. While 
expressive deficits predominantly have to be observed, amotivation and its subdomains should be 
explicitly inquired to assess the patients’ subjective, inner, emotional experience (e.g. Blanchard et 
al., 2011; Marder & Galderisi, 2017; Millan et al., 2014). The PANSS rates asociality with the 
items “poor rapport” (based on observed interpersonal behavior during interview) and “passive, 
apathetic social withdrawal” (based on primary care workers’ or relatives’ reports about patient's 
behavior). In the SANS, avolition/apathy is assessed by three items focusing on subject's 
behavior: “grooming and hygiene”, “impersistence at work/school”, and “physical anergia”. The 
anhedonia/asociality domain includes the patient’s subjective experience (e.g. ability to feel 
intimacy and closeness, sexual interest), as would be appropriate for this dimension of negative 
symptoms; however, it also inquires quantity of interests as well as frequency of social contact. 
Also, anticipatory and consummatory anhedonia are not assessed separately. This also means that 
some items lack clear definition and thus make it harder to extrapolate underlying psychological 
processes (e.g. Blanchard et al., 2011; Garcia-Portilla et al., 2015). Furthermore, using functional 
deficits as a marker for negative symptoms carries the risk of circular reasoning: When assessed 
as part of negative symptoms, functional deficits predict functional outcome (Blanchard et al., 
2011). Finally and of minor importance but to be complete, the SANS surveys the last month and 
thus is not best equipped to monitor change (Blanchard et al., 2011; Millan et al., 2014) 
The following further observer-rated measures were also designed to assess negative 
symptoms or aspects thereof but are not as widely used as the PANSS and SANS (Foussias & 
Remington, 2010; Lincoln, Dollfus, & Lyne, 2017). The BPRS (Overall & Gorham, 1962) and the 
Krawiecka-Manchester Scale (KMS, Krawiecka, Goldberg, and Vaughan (1977)) are global 
measures of psychopathology and mostly disregard the amotivation subdomain. Like the SANS, 
the following instruments were designed specifically for negative symptoms (see Foussias & 
Remington, 2010; Lincoln et al., 2017): 
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• The Schedule for the Deficit Syndrome (SDS, Kirkpatrick et al. (1989)) that taps 
restricted affect, diminished emotional range, poverty of speech, curbing of interests, 
diminished sense of purpose, and diminished social drive. It has not been primarily 
used to measure negative symptoms and their severity but to identify patients with 
deficit syndrome (Foussias & Remington, 2010). 
• The Negative Symptoms Behavior Rating Scale (NSBRS, Pogue-Geile and Harrow 
(1984)) that mainly focuses on expressive deficits. 
• The Negative Symptom Rating Scale (NSRS, Iager, Kirch, & Wyatt, 1985)) that 
includes thought-processes and cognition. 
• The Schedule for Affective Disorders and Schizophrenia – Negative Symptom Scale 
(SADS-NSS, Lewine, Fogg, and Meltzer (1983)) that like the NSBRS and NSRS lacks 
data on its validity. 
• The Negative Symptom Assessment (NSA, Alphs, Summerfelt, Lann, and Muller 
(1989)) that assesses a broad spectrum of negative symptoms but does not represent 
their two-factorial structure. 
• The High Royds Evaluation of Negativity Scale (HEN, Mortimer, McKenna, Lund, 
and Mannuzza (1989)) that includes functioning. 
The five subdomains of negative symptoms can also be assessed more in detail. However, 
most of the following instruments were not specifically designed with patients with schizophrenia 
in mind (see Lincoln et al., 2017). Blunted affect can be assessed with the Emotional Blunting 
Scale (EBS, Abrams and Taylor (1978)), and the Affective Flattening Scale (AFS, Andreasen 
(1979); not specific for schizophrenia). Apathy can be measured with the Apathy Evaluation 
Scale (AES, Marin, Biedrzycki, and Firinciogullari (1991); not specific for schizophrenia), and the 
Lille Apathy Rating Scale (LARS, Sockeel et al. (2006); not specific for schizophrenia). Anhedonia 
can be inquired with the Specific Loss of Interest and Pleasure Scale (SLIPS, Winer, Veilleux, and 
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Ginger (2014); not specific for schizophrenia). Motor functioning and alogia can be tapped with 
the Motor Affective Social Scale (MASS, Trémeau et al. (2008)). 
Interestingly enough, there are only a few established and well validated self-rating 
instruments for psychopathology in schizophrenia – for the most part, interview-based rating 
scales constitute the endpoints of clinical studies. Nevertheless, there are findings indicating that 
patients with schizophrenia can adequately assess at least some negative symptoms: Newer 
questionnaires of negative symptoms correlate strongly with observer-ratings, and patients with 
schizophrenia can differentiate loss of emotion from depressed mood – however, expressive 
deficits seem to be harder to self-assess than deficits in the amotivation domain (Dollfus, Mach, 
& Morello, 2016; Lincoln et al., 2017; Llerena et al., 2013). 
There are three global self-rating scales that also assess negative symptoms: The 
Subjective Experience of Deficits in Schizophrenia (SEDS, Liddle and Barnes (1988)), the 
Subjective Deficit Syndrome Scale (SDSS, Jaeger, Bitter, Czobor, and Volavka (1990)), and the 
Community Assessment of Psychic Experiences (CAPE, Stefanis et al. (2002)). The SEDS and 
the SDSS feature only few items tapping negative symptoms (six of 21 and three of 19, 
respectively) and thus do not cover all domains comprehensively. The CAPE inquires life-time 
psychotic experiences in the general population. Its 14 items tapping negative symptoms are 
derived from the SANS and from a self-rating scale for negative symptoms, the Subjective 
Experience of Negative Symptoms (SENS, Selten, Sijben, van den Bosch, Omloo-Visser, and 
Warmerdam (1993)). Schlier, Jaya, Moritz, and Lincoln (2015) report a factorial analysis of the 
CAPE and found the factors social withdrawal, affective flattening, and avolition for the negative 
symptom items. However, those factors failed to significantly correlate with the PANSS Negative 
Scale and were associated with depression, indicating the need for further optimization (Lincoln 
et al., 2017). 
With regard to self-rating instruments specifically and exclusively for negative symptoms, 
there appear to be the following three (Lincoln et al., 2017): the above-mentioned SENS (Selten 
CHAPTER 1: GENERAL INTRODUCTION 
 
22 
et al., 1993), the Self-Evaluation of Negative Symptoms (SNS, Dollfus et al. (2016)), and the 
Motivation and Pleasure – Self Report (MAP-SR, Llerena et al. (2013)). The MAP-SR is a measure 
under review in this research project and will be described in detail in section 1.8. The SENS 
derives from the SANS and is an interview-based self-rating focusing on awareness and causal 
attribution of as well as distress by negative symptoms. It asks the patient to assess his emotional 
range, quantity of speech and spontaneous elaboration, motivation and energy, expected and felt 
pleasures, as well as preference to be alone and desire for relationships. After each item is 
explained by the interviewer and the patient is given a cue card with possible answers, they are 
asked to rate the items comparing themselves to non-mentally ill people. The inclusion of an 
interviewer introduces a source of influence and makes the SENS quite time-consuming (up to 
45 minutes). Furthermore, so far, there is no data on the SENS’ construct validity, and some 
criticism of the SANS also applies to the SENS, e.g. the inclusion of cognitive deficits (Lincoln et 
al., 2017). Thus, the SNS could be the most up-to-date genuine self-rating instrument for 
negative symptoms (this also since the MAP-SR does not include expressive deficits). It taps 
emotional range and alogia as well as many aspects of amotivation and thus covers all five 
subdomains of negative symptoms. Factor analysis extracted the two factors apathy and emotional 
accounting for 75.2% of the variance, but did not clearly differentiate amotivation and expression 
(Dollfus et al., 2016). The SNS’ convergent and discriminant validity has not yet been evaluated 
comprehensively (Lincoln et al., 2017). 
The subdomain of negative symptoms with the most specific self-assessment scales is 
anhedonia; the following scales are being commonly used (Lincoln et al., 2017): the revised Social 
Anhedonia Scale (SAS, Eckblad, Chapman, Chapman, and Mishlove (1982) (as cited in Lincoln et 
al., 2017)), the revised Physical Anhedonia Scale (PAS, Chapman, Chapman, and Raulin (1976)), 
and the Snaith-Hamilton Pleasure Scale (SHAPS, Snaith et al. (1995)). To help discern 
anticipatory and consummatory pleasure, the Temporal Experience of Pleasure Scale (TEPS, 
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Gard, Gard, Kring, and John (2006)) and the Anticipatory and Consummatory Interpersonal 
Pleasure Scale (ACIPS, Gooding and Pflum (2014)) can be utilized. 
1.8 Integrating Inner Experiences: The CAINS and the MAP-SR 
The above-mentioned National Institute of Mental Health Consensus Development 
Conference on Negative Symptoms endorsed the five domains of negative symptoms and 
emphasized the need for new rating scales to adequately assess them (Kirkpatrick et al., 2006). In 
the following years, two next-generation observer-rated instruments for negative symptoms were 
developed: the BNSS (Kirkpatrick et al., 2011) and the Clinical Assessment Interview for Negative 
Symptoms (CAINS, Kring et al. (2013)). Both interviews were designed with an emphasis on the 
patients’ inner experience and with the two factors expression and amotivation in mind; the two 
factors were confirmed in early exploratory analyses for both scales (Kring et al., 2013; Strauss et 
al., 2012). The CAINS is one of the measures under review in this research project; its 
development process, items and psychometric properties will be described in more detail in the 
following sections. The BNSS has 13 items (rated from 0 = absent to 6 = severe) forming the 
following six subscales: 1) anhedonia (tapping intensity of pleasure during activities, frequency of 
pleasure during activities, and intensity of expected pleasure from future activities), 2) distress 
(asking for presence or absence of distress), 3) asociality (assessing behavior and internal 
experience), 4) avolition (inquiring behavior and internal experience), 5) blunted affect (rating of 
facial and vocal expression as well as expressive gestures), and 6) alogia (rating of quantity of 
speech and spontaneous elaboration). Strauss and Gold (2016) compared the BNSS and the 
CAINS and found good psychometric properties for both scales, endorsing their use in clinical 
trials and laboratory-based studies, and pointing out that both are already being used widely. They 
found high correlations for blunted affect and alogia items between BNSS and CAINS, whilst 
avolition and asociality items correlated moderately to highly. However, the anhedonia items 
showed low convergence. Strauss and Gold (2016) hypothesize that this is due to considerable 
differences both in item content as well as precision of assessment in this domain, proposing that 
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the instruments measure different aspects of anhedonia. The authors conclude that the BNSS 
might be better suited in studies requiring shorter assessment times and high test-retest reliability, 
while the CAINS covers range and frequency of pleasurable activities with more nuances. 
The Clinical Assessment Interview for Negative Symptoms (CAINS) was designed to 
address the conceptual and psychometric limitations of earlier instruments and to provide a 
validated, user-friendly, and comprehensive measure for researchers and clinicians alike (Kring et 
al., 2013). The interview combines observer-ratings of expression, assessments of behavioral 
engagement in relevant activities, and reported inner experiences of motivation and emotion. 
Particularly inner experience is considered pivotal for emotional, social and motivational deficits 
and different from behavior or functional outcome (e.g. Horan, Kring, Gur, Reise, & Blanchard, 
2011; Kring et al., 2013). The interview was developed with input and feedback from industry, 
government, and academia and used a systematic data-analytic approach to scale development 
(Horan et al., 2011; Kring et al., 2013). The CAINS has so far been translated into at least 
Chinese (Mandarin and Cantonese), German, Russian, and Spanish. 
An initial CAINS-beta measure was tested in a pilot study and included 23 items 
oversampling the five domains of negative symptoms (Horan et al., 2011; Kring et al., 2013). 
Horan et al. (2011) evaluated the CAINS-beta in a sample of 281 outpatients with schizophrenia 
or schizoaffective disorder. They found two moderately correlated factors: 1) experiential 
impairments with diminished motivation and enjoyment of social, vocational, and recreational 
activities, and 2) expressive impairments consisting of diminished non-verbal and verbal 
communication. They report good distributional properties, good interrater agreement, 
discriminating anchor points, and preliminary convergent and discriminant validity. Then, the 
CAINS-beta was revised with a multistep data-analytic approach guiding 1) the deletion of 
redundant items, items with poor psychometric properties, and items that did not load clearly on 
one of the factors, and 2) the modification of items to increase discriminatory power and to link 
more clearly to the underlying constructs (Horan et al., 2011; Kring et al., 2013). In the final 
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development study, Kring et al. (2013) evaluated a CAINS version with 16 items sampling 168 
outpatients with schizophrenia or schizoaffective disorder. Three more items were deleted due to 
either a high extent of missing data, redundancy, or failure to load cleanly on one of the two 
factors (Kring et al., 2013). 
The final CAINS (Kring et al., 2013) takes 15 to 30 minutes to administer and consists of 
13 items rated from 0 = no impairment to 4 = severe deficit that are covering the five subdomains of 
negative symptoms. The interview is subdivided in a motivation and pleasure (CAINS-MAP) and an 
expression subscale (CAINS-EXP). CAINS-MAP represents the amotivation factor of negative 
symptoms and taps attitudes, intrinsic motivation as well as subjective experience and expectation 
of pleasure with nine items: 1) motivation for close family/spouse/partner relationships, 2) 
motivation for close friendships and romantic relationships, 3) past week frequency of 
pleasurable social activities, 4) next week frequency of expected pleasurable social activities, 5) 
motivation for work and school activities, 6) next week frequency of expected pleasurable work 
& school activities, 7) motivation for recreational activities, 8) past week frequency of pleasurable 
recreational activities, and 9) next week frequency of expected pleasurable recreational activities. 
CAINS-EXP rater-assesses expressive deficits straightforwardly with four items: 10) facial 
expression, 11) vocal expression, 12) expressive gestures, and 13) quantity of speech. Table 1-1 
showcases i.a. the CAINS’ items and subscales. There is a comprehensive manual providing a 
semi-structured interview and descriptive anchor points as well as illustrative vignettes (the 
German manual can be found in the supplements); training materials, including gold-standard 
videos are available after contact with the developers of the scale (Engel et al., 2014; Kring et al., 
2013). 
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In their final validation study, Kring et al. (2013) used exploratory principal-axis factorial 
analysis and hierarchical cluster analysis and found a two-factorial structure corresponding to the 
two subscales. They report a small to moderate correlation of 0.24 between the subscales, good 
internal consistency (CAINS: Cronbach’s α = 0.76, CAINS-EXP: α = 0.88, CAINS-MAP: α = 
0.74), test-retest reliability (0.69 for both subscales) and interrater-reliability (CAINS-MAP: 0.93, 
CAINS-EXP: 0.77). Good convergent validity was established with regard to other rater 
assessments of negative symptoms (BPRS, SANS; the latter assessed by a different rater to 
counteract shared rater variance). CAINS-MAP showed small to moderate correlations to self-
reports tapping anticipatory and consummatory pleasure as well as sociability. CAINS-EXP 
converged with self-reports on approach and avoidance motivation as well as with a measure 
assessing the subjects positive or negative facial expressions during the interview. Functional 
capacity (skills/capability) was not, but functional outcome (actual behavior) was linked to the 
measure and particularly CAINS-MAP. Thus, the CAINS seems to capture what the patient 
actually does, not what they can do. The authors found adequate discriminant validity regarding 
depression, medication side effects and cognitive functioning. Positive symptoms and agitation, 
however, were correlated with the amotivation subscale. 
In the first validation of the German translation of the CAINS, Engel et al. (2014) 
assessed 53 in- and outpatients with schizophrenia or schizoaffective disorder. They used 
exploratory principal-axis factor analysis and also found the two-factor structure. They report a 
moderate correlation of the two subscales with 0.44. The internal consistency of CAINS and 
CAINS-MAP’s were good (0.87, respectively), while CAINS-EXP’s was acceptable (0.80). Inter-
rater agreement was high for all CAINS items (≥ 0.73). With regard to convergent validity, there 
were high correlations between both CAINS scales and the PANSS Negative Scale. Both 
subscales were moderately related to self-rated consummatory but not anticipatory pleasure. 
CAINS-MAP correlated moderately with the Global Assessment of Functioning (GAF). 
Discriminant validity was good with no significant correlations with positive symptoms as 
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measured with the PANSS, self-rated depression (revised Beck Depression Inventory (BDI-II)) 
and general psychopathology assessed with the PANSS. 
Further validation studies published after the initiation of this research project evaluated 
the Spanish, Korean, Chinese, and the English version of the CAINS and are reported on briefly 
hereinafter. Valiente-Gomez et al. (2015) assessed 100 in- and outpatients and found good inter-
rater and intra-rater reliability. Convergent validity for the Spanish version of the CAINS and its 
subscales was established with the SANS as well as the PANSS Negative Scale. There were 
problems with discriminant validity since significant associations with positive symptoms, general 
psychopathology, and depression were found, however when overall severity of illness was 
controlled for these associations were markedly reduced. CAINS-EXP correlated with 
extrapyramidal symptoms. As in the former two validation studies, the authors employed 
exploratory factor analysis (EFA) and found a two-factorial structure with CAINS-MAP and 
CAINS-EXP that explained 67.44% of variance. In a sample of 119 Korean subjects, Jung, Woo, 
Kim, and Kwak (2016) report a confirmation of the two-factorial structure with CAINS-MAP 
and CAINS-EXP, however, their goodness of fit statistics were not acceptable. They found good 
inter-rater and test-retest reliability as well as convergent and discriminant validity. Xie et al. 
(2018) are to our knowledge the first to use a statistically rigorous confirmatory factor analysis 
approach on the Chinese CAINS in a large scale study with 185 patients with schizophrenia. 
They confirmed the two-factor solution with CAINS-MAP and CAINS-EXP. There was 
convergence of the CAINS with the SANS as well as the PANSS Negative Scale and PANSS 
Global Psychopathology; CAINS-MAP was correlated with consummatory pleasure. 
Discriminant validity to positive symptoms was established, but depression, extrapyramidal 
symptoms and cognitive deficits were not assessed separately. The authors found good 
discriminant validity when differentiating negative symptoms in people with schizophrenia, 
nonpsychotic first-degree relatives and people with social anhedonia. In Singapore, Rekhi, Ang, 
Yuen, Ng, and Lee (2019) initially found no acceptable fit for the two-factorial structure. After 
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exploratory factor analysis (split-half sample of 133 subjects), a confirmatory factor analysis 
(CFA) confirmed four factors: motivation and pleasure social, motivation and pleasure vocational, motivation 
and pleasure recreational, and expression (split-half sample of 141 subjects). Convergent validity with 
the SANS and the PANSS Negative Scores as well as discriminant validity with the positive and 
depressive symptoms was established. 
Developing and implementing valid self-report measures seems to be the next logical step 
with regard to the current intensified focus on the patients’ subjective experience. Those 
instruments could save cost and time when identifying patients with a relevant subjective burden 
and facilitate online research as well as large scale panel studies with community sampling. 
As already mentioned in section 1.7, the Motivation and Pleasure Scale – Self Report 
(MAP-SR, Llerena et al. (2013)), is one of the few questionnaires assessing negative symptoms. 
Its precursor, the Clinical Assessment Interview for Negative Symptoms – Self Report (CAINS-
SR, Park et al. (2012)) derives from the CAINS and was developed as a 30-item questionnaire 
assessing avolition, anhedonia and asociality – dubbed the experiential domain – and blunted 
affect and alogia – the expressive domain. They assessed 69 patients with schizophrenia or 
schizoaffective disorder and found good internal consistency, good convergent validity with 
CAINS-MAP, and good discriminant validity for the experience subscale. However, the 
expression subscale had poor psychometric properties. The authors concluded that self-reports 
of negative symptoms should focus on the experiential domain and then might complement the 
clinician-rated measures. 
Llerena et al. (2013) aimed to refine the CAINS-SR by focusing exclusively on self-
reported deficits in motivation and pleasure, arguing that they encompass many of the core 
deficits of negative symptoms that are directly related to functional impairment. The resulting 
MAP-SR is a self-report version of the CAINS-MAP subscale and does not cover all five 
negative symptom domains. Llerena et al. (2013) assessed a sample of 37 outpatients with 
schizophrenia or schizoaffective disorder and reduced an 18-item version of the MAP-SR to 15 
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items due to low item-total correlations for three items. The MAP-SR is rated on a 5-point Likert 
scale with higher scores reflecting greater pathology. Nine items assess the construct avolition by 
inquiring feelings and motivations about close, caring relationships as well as motivation and 
effort to engage in activities. Three of the MAP-SR’s items assess anhedonia by asking about 
expected and experienced recreational and work pleasure. Asociality is measured by three items 
inquiring expected and experienced social pleasure. Table 1-1 lists the MAP-SR’s items and 
domains as well as corresponding CAINS items and constructs. 
For their sample of 37 patients, Llerena et al. (2013) report good internal consistency for 
the 15-item MAP-SR. Convergent validity was established with regard to the CAINS-MAP, social 
anhedonia, social closeness, and clinician-rated social functioning. No significant correlations 
were found for observer-rated positive symptoms and depression/anxiety as well as general 
cognitive abilities signifying adequate discriminant validity. Further validation studies were 
undertaken by Engel and Lincoln (2016) for the German version of the MAP-SR (n = 50) and J.-
S. Kim et al. (2016) for the Korean MAP-SR (n = 137). Both found good internal consistency. 
Convergent validity was strong to moderate regarding correlations to CAINS-MAP as well as the 
PANSS Negative Scale (Engel & Lincoln, 2016) and the SANS (J.-S. Kim et al., 2016). No 
significant correlation with CAINS-EXP was found in the German study (Engel & Lincoln, 
2016), whereas a weak correlation was reported by J.-S. Kim et al. (2016). Discriminant validity 
was widely established: Both research teams found no significant correlation with positive 
symptoms and rater-assessed depression/anxiety. J.-S. Kim et al. (2016) also assessed cognitive 
deficits and found no significant association. Engel and Lincoln (2016) found a moderate but 
significant correlation with self-rated depression. 
The MAP-SR still is at an early stage with regard to the usual procedures in validating new 
measures. It was constructed to represent the amotivation factor of negative symptoms, but there 
is no empirical analysis of its factorial structure yet. The initial scale development study’s sample 
size was quite small and the measures used to determine convergent and discriminant validity 
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have not been very comprehensive in the original as well as the German study. Moreover, both 
Llerena et al. (2013) and Engel and Lincoln (2016) suggested further research on the temporal 
stability of the MAP-SR. 
 
2. Objective and Outline 
Summarizing this chapter, negative symptoms are prevalent in most patients with 
schizophrenia at some point of the illness. They constitute an important predictor of course of 
illness as well as social and occupational functioning. Clinically effective interventions are scarce 
and the negative symptom domain remains a major challenge concerning treatment. For negative 
symptoms to become a reliable primary endpoint in treatment studies, clear operationalization 
and construct validation is needed. This holds true for rater-assessments as well as self-report 
measures, which could assist clinicians and researchers in identifying patients with a relevant 
subjective burden. It seems of particular importance to reliably differentiate negative and 
depressive symptoms, since depression is the most important indicator for completed suicide in 
patients with schizophrenia and its treatment in this population remains inadequate. 
This thesis aims to contribute to current research on instruments measuring negative 
symptoms. In general, the questions are addressed, whether the CAINS reliably measures the 
construct negative symptoms and the MAP-SR the subdomain amotivation as well as whether 
both instruments can differentiate subjects with schizophrenia, those with depression and healthy 
controls. 
In chapter 2, the research on the observer-rated CAINS’ psychometric properties is 
presented. This is a confirmation of and substantial expansion on Engel et al. (2014) with a larger 
sample, a comprehensive multitrait-multimethod approach to convergent and discriminant 
validity, and an assessment of test-retest reliability. Additionally, at the conception of the research 
project there had been no confirmatory factorial analysis (CFA) of the CAINS’ two-factorial 
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structure yet. The CAINS’ two-factorial structure is confirmed, then, internal consistency, 
interrater and test-retest reliability as well as convergent and discriminant validity are assessed and 
discussed. Chapter 3 contains a thorough and critical assessment of the self-rating instrument 
MAP-SR with analysis at item level as well as of the scale and found subscales. There was no 
previous assessment of the MAP-SR’s test-retest reliability and its factorial structure had not been 
empirically analyzed. The MAP-SR’s factorial structure, internal consistency and test-retest 
reliability as well as the items’ convergent validity and the scales’ convergent and discriminant 
validity are examined and appraised. Chapter 4 comprises research on the discriminatory power 
of the CAINS, MAP-SR, Hamilton Rating Scale for Depression (HAMD-17, Hamilton (1967)), 
and Beck Depression Inventory (BDI, Hautzinger (1991)) when assessing subjects with 
schizophrenia, subjects with MDE, and healthy controls. In chapter 5 a general discussion of the 
results as well as an overarching outlook is presented. 
Chapters 1 to 3 have been accepted for publication in their respective form and are thus 
separately readable manuscripts. This results in overlapping contents of this introduction, the 
general discussion, and the empirical chapters.  
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CHAPTER 2: Evidence for Two Distinct Domains of 
Negative Symptoms: Confirming the Factorial 
Structure of the CAINS1 
  
 
1 This chapter was accepted for publication as: Richter, J., Hesse, K., Schreiber, L., Burmeister, C. P., Eberle, M.-C., 
Eckstein, K. N., Zimmermann, L., Wildgruber, D., & Klingberg, S. (2019). Evidence for Two Distinct Domains of 
Negative Symptoms: Confirming the Factorial Structure of the CAINS. Psychiatry Research, 271, 693-701. Journal 
formatting was adapted to fit this thesis’ layout, citation style, and table and figure captions. 
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Abstract 
Negative symptoms are an important predictor of course of illness as well as social and 
occupational functioning. Clinically effective interventions are scarce. For negative symptoms to 
become a reliable primary endpoint in treatment studies, clear operationalization and construct 
validation is needed. Recent factor analyses mostly find two main factors for negative symptoms: 
diminished expression und amotivation/anhedonia. The Clinical Assessment Interview for 
Negative Symptoms (CAINS) consists of the subscales “motivation and pleasure” and 
“expression”. We assessed three samples of subjects with schizophrenia (n = 105) for different 
aspects of the scale's reliability and validity. A confirmatory factor analysis (CFA) of the CAINS 
confirmed its two-factorial structure. The subscales had distinct correlational profiles: 
"Motivation and pleasure" was strongly associated with functional outcome and depression and 
further with neurocognition, positive symptoms and social cognition. "Expression" seems 
independent of sources of secondary negative symptoms and neurocognition. We found good 
internal consistency and interrater agreement. Test-retest reliability was moderate for the CAINS 
and its “expression” subscale and low for the “motivation and pleasure” subscale. Our findings 
indicate that the CAINS differentiates reliably between the two main domains of negative 
symptoms with some questions remaining concerning the validity of the “motivation and 
pleasure” subscale. 
 
1. Introduction 
Psychotic disorders are characterized by cognitive dysfunctions as well as positive and 
negative symptoms (e.g. Owen, Sawa, & Mortensen, 2016). Positive symptoms have been 
relatively well defined for quite some time, whereas the construct „negative symptoms“ wasn’t 
theoretically refined and empirically tested until the 1980s by – amongst others – Andreasen 
(1982). The scientific discussion intensified with the development of interventions to treat 
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negative symptoms, since they are an important predictor of e.g. course of illness as well as social 
and occupational functioning (e.g. Kaiser et al., 2017; Marder & Galderisi, 2017). A meta-analysis 
on treatments for negative symptoms found no clinically effective (even if statistically significant) 
interventions so far (Fusar-Poli et al., 2015). The authors called for the development of new, 
specific treatments. According to Lutgens, Gariepy, and Malla (2017)’s meta-analysis on non-
biological interventions, cognitive-behavioral therapy, skills-based training (and particularly social 
skills training (see also Kurtz & Mueser, 2008; Turner et al., 2018), exercise, and music treatments 
are promising. For negative symptoms to become a reliable primary endpoint in treatment 
studies, clear operationalization and construct validation is needed (e.g. Marder & Galderisi, 
2017). 
1.1 Subdomains of Negative Symptoms 
The National Institute of Mental Health consensus document (Kirkpatrick, Fenton, 
Carpenter, & Marder, 2006) has reviewed the concept “negative symptoms” that refers to 
Andreasen (1982).They identified five dimensions of negative symptoms: emotional blunting 
(lower intensity and range of verbal and non-verbal emotional expression), alogia (lack of speech, 
latency, poverty of speech content), avolition (lack of drive and motivation), anhedonia (inability 
to experience pleasure) and social withdrawal (reduced interest in, motivation for and enjoyment 
of social interaction and close relationships). Concerning anhedonia, there are findings indicating 
that patients with schizophrenia mainly show a deficit in anticipatory pleasure whereas 
consummatory pleasure is largely unaffected (Gard, Kring, Gard, Horan, & Green, 2007; 
Lambert et al., 2018; Wu et al., 2017). As there are different pathways leading to negative 
symptoms, the term secondary negative symptoms has been introduced and explored (Carpenter, 
Heinrichs, & Wagman, 1988; Kirschner, Aleman, & Kaiser, 2017). Kirschner et al. (2017) argue 
that increased scores on negative symptom scales can be caused by depression (e.g. anhedonia 
(e.g. Lako et al., 2012)), positive symptoms (e.g. social withdrawal (e.g. Kelley, van Kammen, & 
Allen, 1999; Tandon et al., 2000)), side effects of medication (e.g. emotional blunting (Kelley et 
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al., 1999; Prosser et al., 1987)), substance use (e.g. amotivation (e.g. Rovai et al., 2013)), and 
environmental conditions like social deprivation (e.g. avolition, social withdrawal (Kasanova, 
Oorschot, & Myin-Germeys, 2018; Oshima, Mino, & Inomata, 2005)). In contrast, primary 
negative symptoms are thought to be directly linked to schizophrenia. 
1.2 Relationships with Other Symptom Domains 
When taking into account the phase of illness, positive symptoms and depressive 
symptoms don’t seem to systematically correlate with negative symptoms. For positive 
symptoms, Peralta, Cuesta, Martinez-Larrea, and Serrano (2000) report a non-significant 
correlation of 0.23 on admission but a significant and strong correlation of 0.57 on hospital 
discharge. Others found no significant correlations with negative symptoms (Schrank, Amering, 
Hay, Weber, & Sibitz, 2014; Wallwork, Fortgang, Hashimoto, Weinberger, & Dickinson, 2012). 
Regarding depression, Peralta et al. (2000) found no relationship with negative symptoms on 
admission (0.01) and a large correlation (0.51) on discharge. Others found no significant (Kim et 
al., 2006; Wallwork et al., 2012) or a significant moderate relationship (Schrank et al., 2014) of 
negative and depressive symptoms. For cognitive dysfunction, there are small to moderate 
correlations with negative symptoms (0.07 to 0.29; Dominguez, Viechtbauer, Simons, van Os, & 
Krabbendam, 2009; Ventura, Hellemann, Thames, Koellner, & Nuechterlein, 2009). 
1.3 Two-Factorial Structure of Negative Symptoms 
 Blanchard and Cohen (2006) present an overview of analyses of the factorial structure of 
negative symptoms. They found evidence for two replicable factors encompassing the above 
mentioned subdomains in factorial analyses of the Scale for the Assessment of Negative 
Symptoms (SANS), the Schedule for the Deficit Syndrome (SDS), the Positive and Negative 
Syndrome Scale (PANSS; two-factorial structure also found by Liemburg et al. (2013)) and the 
Brief Psychiatric Rating Scale (BPRS). The first factor entails “diminished expression” covering 
emotional blunting and alogia, the second “amotivation” which contains avolition, anhedonia and 
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social withdrawal. When evaluated, inappropriate affect, poverty of speech content, and reduced 
attention load on a third factor representing cognitive deficits/disorganization, which are at this 
point not thought of as part of the negative symptom domain (e.g. Marder & Galderisi, 2017). 
The two main factors “diminished expression” and “amotivation” correlate moderately (0.47 to 
0.57) indicating a common underlying process (Blanchard & Cohen, 2006; Foussias & 
Remington, 2010; Kirkpatrick, 2014). 
In a review, Kaiser et al. (2017) summarized that models of amotivation are currently 
converging on reward system dysfunction and aspects of goal directed behavior, while models of 
expressive deficits are still in an early phase of development. They find behavioral and 
neuroimaging studies to support distinct underlying mechanisms. Expressive deficits seem to be 
more persistent (Kelley, Haas, & van Kammen, 2008) while amotivation correlates stronger with 
functional outcome (e.g. Fervaha, Foussias, Agid, & Remington, 2014). There is preliminary 
evidence for different outcomes for the two symptom domains concerning psychotherapeutic 
and pharmacological treatments as well as relapse (e.g. Kaiser et al., 2017; Riehle, Pillny, & 
Lincoln, 2017; Sayers, Curran, & Mueser, 1996). 
1.4 The Clinical Assessment Interview for Negative Symptoms (CAINS) 
Until recently, the SANS and the PANSS Negative Scale were most commonly used to 
assess negative symptoms. Both scales have been criticized for including items which presumably 
are not part of the negative syndrome and for featuring items that are not clearly defined. Also, 
the scales mostly assess behavior and rarely specifically inquire the patients’ subjective experience. 
Overall, they don’t seem to reflect the current state of the art in research anymore (Blanchard, 
Kring, Horan, & Gur, 2011; Marder & Galderisi, 2017; Millan, Fone, Steckler, & Horan, 2014). 
The Marder Negative Symptom Factor Score (Marder Negative; sum of PANSS items N1 to N4 
and N6) aims to remediate some of the problems of the PANSS Negative Scale (Marder, Davis, 
& Chouinard, 1997). Both the Brief Negative Symptom Scale (BNSS, Strauss et al. (2012)) and 
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the measure under review here, the Clinical Assessment Interview for Negative Symptoms 
(CAINS, Kring, Gur, Blanchard, Horan, and Reise (2013)), are more recent instruments that refer 
to the above-mentioned two factors and confirmed those in exploratory analyses (Kring et al., 
2013; Strauss et al., 2012). Both instruments facilitate differentiating amotivation and expression 
and thus advance the evaluation of new treatment options (Strauss & Gold, 2016). 
 
Notes. CAINS-MAP = “motivation and pleasure” subscale; CAINS-EXP = “expression” subscale. 
Figure 2-1. CAINS subscales with items and item content. 
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The CAINS encompasses the five subdomains blunted affect, poverty of speech, 
avolition, anhedonia and social withdrawal. When assessing the “avolition/amotivation” factor, it 
focuses on the patients’ inner experience. This is considered pivotal for emotional, social and 
motivational deficits and seen as different from behavior or functional outcome (e.g. Kring et al., 
2013). The CAINS’ structure can be seen in figure 2-1 and consists of a “motivation and 
pleasure” subscale (CAINS-MAP) and an “expression” subscale (CAINS-EXP). CAINS-MAP 
taps attitudes, intrinsic motivation as well as subjective experience and expectation of pleasure 
with nine items. CAINS-EXP rater-assesses expressive deficits straightforwardly with four items. 
When validating the CAINS, Kring et al. (2013) found a two-factorial structure using 
exploratory principal-axis factorial analysis and hierarchical cluster analysis. They reported a 
correlation of 0.24 between the subscales, good internal consistency (CAINS: Cronbach’s α = 
0.76, CAINS-EXP: α = 0.88, CAINS-MAP: α = 0.74), test-retest reliability (0.69 for both scales) 
and interrater-reliability (CAINS-MAP: 0.93, CAINS-EXP: 0.77). Good convergent validity was 
established with regard to other rater assessments of negative symptoms (BPRS, SANS), self-
reports tapping pleasure, motivation and sociability and measures concerning the assessment of 
facial emotion expressions. Functional capacity (skills/capability) was not, but functional 
outcome (actual behavior) was linked to the measure. The authors found adequate discriminant 
validity regarding depression, medication side effects and cognitive functioning. However, 
positive symptoms and agitation were correlated with the “motivation and pleasure” subscale. 
 Engel, Fritzsche, and Lincoln (2014) evaluated a German translation of the CAINS. Their 
exploratory principal-axis factor analysis also found the two-factor structure. Here, the two 
subscales were moderately correlated (0.44). The CAINS’ overall internal consistency and the 
CAINS-MAP’s were good (0.87, respectively), the CAINS-EXP’s was acceptable (0.80). Inter-
rater agreement was high for all CAINS items (≥ 0.73). Concerning convergent validity, there 
were high correlations between both CAINS scales and the PANSS Negative Scale. The 
subscales were significantly negatively related to self-rated consummatory pleasure but not to 
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anticipatory pleasure. Discriminant validity was good with no significant correlations with 
positive symptoms, depression and general psychopathology. CAINS-MAP was significantly 
correlated with the Global Assessment of Functioning (GAF). 
1.5 Objectives 
This validation of the German CAINS’s psychometric properties aims to confirm and 
expand on Engel et al. (2014). We analyze a larger sample and – to our knowledge – this is the 
second confirmatory factorial analysis (CFA; the first being a Chinese sample (Xie et al., 2018)) of 
the CAINS’ two-factorial structure. This is complemented by a comprehensive multitrait-
multimethod approach to assess convergent and discriminant validity of the two subscales. Test-
retest reliability has not been reported for the German version as of yet; we assessed this, as well 
as interrater reliability. 
 
2. Methods 
2.1 Participants 
Three independently collected samples were used: a “convergent and discriminant 
validity” sample (sample V), a “test-retest and interrater reliability” sample (sample R) and an 
additional sample to increase the sample size of the pooled “confirmatory factor analysis” sample 
(CFA sample). Inclusion criteria across all samples were diagnosis of a psychotic disorder 
according to DSM-IV, age 18 to 65 years, sufficient German language skills, normal or corrected 
to normal vision and hearing as well as capability to give consent. Exclusion criteria were 
substance dependence as the leading clinical problem and intellectual disability (IQ < 70, 
approximated by level of education). In addition to these common inclusion and exclusion 
criteria, there were sample-specific differences.  
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Sample V was used to assess the CAINS’ convergent and discriminant validity and 
included 70 outpatients in a stable phase. Since sample V was the baseline examination of a study 
that aimed to improve negative symptoms using individual- and group-CBT, the participants had 
to have relevant negative symptoms (sum of PANSS items N1 to 4, N6, G7 and G16 ≥ 10) and 
to be in outpatient treatment to be included. Sample V’s additional exclusion criteria were severe 
depressive symptoms (PANSS, G5 > 4), structural brain lesions, severe extrapyramidal side 
effects (Modified Simpson-Angus Rating Scale (MSAS) > 11), and current psychotherapeutic 
treatment. The diagnosis of a psychotic disorder according to DSM-IV was established using the 
Structured Clinical Interview for DSM-IV (SCID-I) for sample V. Sample V’s participants 
received a monetary compensation for their assessment, the other samples did not. 
Sample R was primarily used to assess the scale’s interrater- and test-retest reliability and 
comprised 25 in-patients; 19 of whom were still available for the second assessment. In sample R, 
the assessment was videotaped, so the participants had to agree to this. 
The additional sample comprised 12 inpatients and outpatients used to increase the 
overall sample size for the CFA. Sample R and the additional sample were diagnosed with the 
German Brief Diagnostic Interview of Mental Disorders (Mini-DIPS). 
Both sample V and R as well as the additional sample (n = 105 because of overlap between the 
samples) were used for factorial analysis and to assess the internal consistency of the measure. 
Demographic and clinical characteristics of the samples can be found in table 2-1. 
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Table 2-1 
 
Note. Univ. = University; PANSS = Positive and Negative Syndrome Scale; CDSS = Calgary Depression Scale for 
Schizophrenia; PSP = Personal and Social Performance Scale. 
2.2 Procedures and Measures 
The study protocol was approved by the ethics committee of the University of 
Tuebingen’s medical faculty. After giving informed consent, all screened participants that met 
inclusion criteria were interviewed using the following measures: 1) a structured interview to 
obtain basic demographic data, 2) the PANSS (30-item clinician-rated measure of psychosis 
symptoms scored on a 7-point Likert scale ranging from 1 (absent) to 7 (extreme)) as well as 3) 
the CAINS (13-item semi-structured interview scored on a 5-point Likert scale ranging from 0 
(no impairment) to 4 (severe deficit)). All raters were trained by observing experienced raters 
conduct the CAINS, applying the CAINS themselves using the manual and discussing the 
assessment amongst each other. 
Demographics of Sample V, Sample R and the CFA-Sample
Sample V (n =70) Sample R (n =25) CFA-Sample (n =105)
Age (yrs) 39.92 (11.06) 38.16 (10.68) 39.11 (10.94)
Male (%) 71.4 60 69.5
Age at 1st Hospitalization (yrs) 25.82   (8.64) 24.04   (8.10) 25.47   (8.13)
Univ. Entrance Qualification (%) 58.6 44.0 60.0
Diagnosis (%)
  Schizophrenia 85.7 76 85
  Schizoaffective disorder 14.3 24 15
PANSS Total Score 62.16 (12.35) 66.80 (20.87) 63.87 (14.83) (n=93)
PANSS Positive Score 12.79   (4.67) 13.36   (5.31) 13.00   (4.86) (n=93)
PANSS Marder Negative Score 20.27   (4.75) 14.20   (7.65) 16.21   (4.86)
CDSS Total Score   4.23   (4.30)
PSP 48.40 (13.00)
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Sample V was assessed by two raters (MCE, KK); this took approximately four hours and 
included the following additional measures: 1) the Time Budget Measure (TBM) whose 
structured retrospective assessment of the past week is intended to reflect the actual level of 
activity, 2) the Calgary Depression Scale for Schizophrenia (CDSS), 3) the Personal and Social 
Performance Scale (PSP) as a rating of psychosocial functioning as well as 3) the Modified 
Simpson-Angus Scale (MSAS) assessing extrapyramidal side effects. Additionally, there was a 
performance assessment of social skills using role play, the Social Skills Performance Assessment 
(SSPA), which was audio recorded. Furthermore, we assessed cognitive functioning employing 1) 
the Trail Making Test A and B (TMT-A, TMT-B), 2) the German version of the auditory verbal 
learning test (VLMT), 3) the Tower of London (ToL) as well as 4) the Wechsler Adult 
Intelligence Scale‘s Digit Span task (WAIS-IV-DS). Lastly, the participants were asked to fill in 
additional questionnaires: 1) the Frankfurt Self-Concept Scales (FSKN), assessing components of 
self-concept including the subscale “appreciation by others” as a measure of social cognition 
(FSWA; tapping feelings of insufficiency and rejection in social situations) and 2) the Temporal 
Experience of Pleasure Scale (TEPS), assessing anticipatory und consummatory pleasure. 
Sample R’s initial assessment lasted approximately one hour during which the CAINS 
interview was videotaped. The raters CB and LS conducted one half of the interviews, 
respectively and assessed the videos of the other half. 14 (+/- 5) days after the first assessment, 
participants were evaluated again, which took about 25 minutes. 
The additional sample’s assessment was done by the raters LH and SR, included further 
measures and took approximately 1.5 hours. 
The German versions of the CAINS and TEPS were kindly made available to us by the 
research group led by Tania Lincoln, Department of Clinical Psychology and Psychotherapy, 
University of Hamburg. The German manual and rating sheet of the CAINS can be found in our 
supplementary data as well as downloaded free of charge under the creative commons license 
here: http://dx.doi.org/10.23668/psycharchives.775. The English versions of the TBM and 
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SSPA were translated into German by our research group and retranslated by an English native 
speaker. Differences to the original English versions were discussed among the translators and a 
consensus was agreed on. 
2.3 Data Analysis 
For demographic data a rate of missing items ≤ 10% was not reported. When calculating 
the scale composites, a rate of 5% and 10% of missing values for assessments and self-ratings 
respectively were tolerated and replaced by the scale’s mean. Data points with more missing items 
were excluded from the respective analysis. The data quality of the CAINS, its subscales and 
items was high with no missing data. 
Using SPSS v24 and AMOS v21, we assessed 1) the CAINS’ and its two subscales’ 
internal consistency, test-retest reliability and interrater reliability, 2) the CAINS’ latent structure 
using confirmatory factor analysis (CFA) and 3) the scales’ and its subscales’ convergent and 
discriminant validity. 
We tested for normal distribution and homoscedasticity. Pearson or Spearman 
correlations respectively were used to evaluate test-retest reliability as well as convergent and 
discriminant validity. There, Holm-Bonferroni sequential correction was used to deal with the 
multiple comparisons problem. For interrater reliability the average Intraclass Correlation 
Coefficient (ICC) estimate and 95% confidence intervals were calculated based on a mean-rating 
(k = 2), absolute-agreement, two-way random model. 
Concerning confirmatory factor analysis, we follow the recommendations of Jackson, 
Gillaspy Jr, and Purc-Stephenson (2009). With regards to sample size, Jackson, Voth, and Frey 
(2013) propose to take p/f ratios (number of measured variables loading on each factor), number 
of latent variables and loading size into account. Their results suggest that for our two factors, a 
p/f of 4 and 9 and expected loading sizes between 0.4 and 0.9, a sample size of 50 to 100 could 
be sufficient. Curve estimation for all relationships in our model found them to be sufficiently 
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linear. We then assessed univariate and multivariate normality. Skewness and kurtosis values for 
the items were all < |2| and < 7 respectively, suggesting adequately normal distribution. Mardia's 
coefficient, however, was 9.21 with a critical ratio of 2.39 (cut-off < 1.96) which suggests 
significant – but not excessive – multivariate non-normality (Byrne, 2010). There were no 
multivariate outliers identified via Mahalanobis distance at α = 0.001 and nine at α = 0.05 
(Tabachnick & Fidell, 2007); there was no justification for the exclusion of any outliers (Byrne, 
2010). 
For the CFA, the analysis was performed on the observed covariance matrix. We used 
maximum likelihood estimation which is thought to be robust to minor deviations from 
normality (e.g. Chou & Bentler, 1995). To account for the multivariate non-normality we used 
Bollen-Stine bootstrapping to adjust p-values for the c2 goodness-of-fit test of our model (Byrne, 
2010). We report goodness-of-fit statistics CMIN, Comparative Fit Index (CFI; > 0.9 indicating 
adequate and > 0.95 good model fit), Root Mean Square Error of Approximation (RMSEA; < 
0.08 is considered adequate (Browne & Cudeck, 1992), < 0.05 good (Steiger, 1990)), and Akaike 
Information Criterion (AIC; with smaller numbers indicating better fit). Fan, Thompson, and 
Wang (1999) consider RMSEA and CFI to be less sensitive to sample size compared to other 
indices. We used the bias-corrected percentile method to calculate confidence intervals for the 
standardized regression weights and covariances (Byrne, 2010). 
 
3. Results 
3.1 Internal Consistency (CFA Sample) 
The internal consistency of the scale was good: Cronbach’s α = 0.87, with no “α if item 
deleted” > 0.87. For the subscales, we found good internal consistency as well: CAINS-MAP’s 
Cronbach’s α = 0.83, CAINS-EXP’s Cronbach’s α = 0.86. 
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3.2 Interrater Reliability (Sample R) 
The single measure ICC was 0.81 (CI 0.61 - 0.91; (F(24) = 9.17, p < 0.001) indicating 
good reliability. For the subscales, interrater reliability was 0.81 for CAINS-MAP (CI 0.61 - 0.91; 
(F(24) = 9.23, p < 0.001) and 0.80 (CI 0.60 - 0.91; (F(24) = 8.70, p < 0.001) for CAINS-EXP. 
3.3 Test-Retest Reliability (Sample R) 
For the CAINS we found a test-retest reliability of 0.71, p = 0.001, which is considered 
acceptable. CAINS-EXP had good test-retest reliability (r = 0.82, p < 0.001); CAINS-MAP’s was 
poor to moderate (rS = 0.57, p = 0.011). 
3.4 Confirmatory Factor Analysis (CFA Sample) 
The CFA of a two-factorial structure of the CAINS with items 1 to 9 loading on the 
“motivation and pleasure” factor and items 10 to 13 loading on the “expression” factor had no 
cross-loadings but proved to be no good fit for the data (c2(64) = 197.57, Bollen-Stine p < 0.001; 
CFI = 0.79, RMSEA = 0.14 (90%-CI 0.12 - 0.16), AIC = 251.57). Inspection of modification 
indices showed high covariances between some error terms of the “motivation and pleasure” 
scale. We iteratively included them in post hoc model fitting to account for the relevant item 
overlaps in the “motivation and pleasure” scale (e.g. Jöreskog & Long, 1993). The final model 
still had items 1 to 9 loading on the “motivation and pleasure” factor and items 10 to 13 loading 
on the “expression” factor and included overlap of items 3 and 4, 5 and 6, as well as 4 and 9: 
c2(61) = 93.28, Bollen-Stine bootstrap p < 0.98; CFI = 0.95, RMSEA = 0.07 (90%-CI 0.04 - 
0.10), and AIC = 153.28. Its structure, standardized regression weights and covariances can be 
found in figure 2-2. We compared the two nested models and found a significantly worse fit for 
the original model: ∆c2(3) = 104.29, p < 0.001. Table 2-2 shows estimates and confidence 
intervals for its standardized regression weights as well as covariances of the subscales.  
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Notes. CAINS.MAP = “motivation and pleasure” subscale; CAINS.EXP = “expression” subscale; item 1 to item 13 
= CAINS items. 
Figure 2-2. Plot of the two-factor-CFA (final model) with covariances and standardized 
regression weights. 
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Table 2-2 
 
Note. CIs = confidence intervals; CAINS-MAP = “motivation and pleasure” subscale; CAINS-EXP = “expression” 
subscale, item 1 to item 13 = CAINS items. 
3.5 Convergent and Discriminant Validity (Sample V) 
Table 2-3 shows correlations of the CAINS and its subscales CAINS-MAP and -EXP 
with supposed related and unrelated domains. The CAINS-MAP was found to be strongly 
associated with functional outcome and depression and further with neurocognition, positive 
symptoms and social cognition. CAINS-EXP was independent from positive and extrapyramidal 
symptoms, depression and neurocognition.  
Parameters Estimates (CIs) p
CAINS-MAP item 1 0.33  (0.08 - 0.55)   0.011
                       item 2 0.52  (0.30 - 0.67)   0.002
                       item 3 0.58  (0.37 - 0.72)   0.002
                       item 4 0.53  (0.30 - 0.68)   0.001
                       item 5 0.39  (0.18 - 0.55)   0.001
                       item 6 0.24 (-0.03 - 0.45)   0.082
                       item 7 0.85  (0.77 - 0.91)   0.001
                       item 8 0.89  (0.80 - 0.95)   0.002
                       item 9 0.74  (0.59 - 0.84)   0.001
CAINS-EXP item 10 0.81  (0.71 - 0.88)   0.001
                       item 11 0.92  (0.83 - 0.98)   0.001
                       item 12 0.72  (0.58 - 0.83)   0.001
                       item 13 0.69  (0.55 - 0.80)   0.001
CAINS-MAP - CAINS-EXP 0.37  (0.19 - 0.56)   0.001
item 5 - item 6 0.74  (0.47 - 1.07) <0.001
item 3 - item 4 0.35  (0.23 - 0.53) <0.001
item 4 - item 9 0.23  (0.14 - 0.33)   0.001
Estimates&Confidence Intervals for the Final Model’s 
Standardized Regression Weights&Covariances
Standardized Regression Weights
Covariances
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4. Discussion 
To further establish the two factors of negative symptoms, firstly the instruments that try 
to measure them have to have adequate reliability. Secondly, distinct profiles should be found and 
replicated for structure as well as content. Summarizing the results, we found good internal 
consistency for the CAINS and its subscales. Interrater agreement was good for all scales. We 
confirmed the CAINS’ two-factorial structure with minor adjustments for the “motivation and 
pleasure” subscale. The two subscales showed distinct patterns of association with related 
symptoms and domains. 
4.1 Test-Retest Reliability 
This is the first evaluation of  the test-retest reliability of  the German translation of  the 
CAINS, which was in a medium range for the CAINS (r = 0.71) and its “expression” subscale (r 
= 0.74) and low for the “motivation and pleasure” subscale (r = 0.57). The CAINS' and CAINS-
EXP's stability is in line with the original validation study (Kring et al. (2013), n = 162, two-week 
interval, r = 0.69, for CAINS-EXP and CAINS-MAP), and two further studies (Blanchard et al. 
(2017), n = 447, three-month interval, CAINS-EXP: r = 0.75, CAINS-MAP: r = 0.80; Xie et al. 
(2018), n = 23, two-week interval, r = 0.68 for CAINS, 0.63 for CAINS-EXP and 0.68 for 
CAINS-MAP). We expected higher test-retest reliability for the CAINS-MAP considering the 
short period of time between the assessments and the widely reported (moderate) stability of 
negative symptoms (e.g. Ventura et al., 2015). We found no blatant differences between the other 
studies’ and our samples that could explain the differences in the CAINS-MAP’s test-retest 
reliability. However, our test-retest reliability sample R is small and mainly consists of  in-patients 
(although most were in the stabilization phase). Thus, we might have measured a non-negligible 
amount of  possibly less stable secondary negative symptoms. Consistent with our results, both 
Galderisi et al. (2013) and Kelley et al. (2008) found diminished expression to be more persistent 
across time; amotivation seems to be more sensitive to changes. The CAINS-MAP’s focus on 
CHAPTER 2: CONFIRMING THE FACTORIAL STRUCTURE OF THE CAINS 
 
51 
inner experience as opposed to observable behavior could entail a higher variability of  answers 
when retesting. We think for the CAINS, further evaluation of  mainly the “motivation and 
pleasure” subscale’s stability is needed; overall, the stability of  all different aspects of  negative 
symptoms (deficit syndrome, persistent negative syndrome, primary and secondary negative 
symptoms as well as the two (possibly five) factors of  negative symptoms) seems to be worth 
looking into. 
4.2 Confirmatory Factor Analysis 
Since this is a smaller sample, we did not compare different factorial models. There is a 
recent comprehensive factor-analysis on the Brief Negative Symptom Scale (BNSS, Strauss et al. 
(2012)) that found the best fit for a hierarchical 5-factor model with two second-order factors 
reflecting “expression” and “amotivation” as well as 5 first-order factors reflecting blunted affect, 
alogia, anhedonia, avolition, and asociality which seems worth exploring in further studies 
(Ahmed et al., 2018). However, we confirmed previous exploratory analyses of the CAINS that 
overwhelmingly yielded two factors. We consider the CFA’s final model an overall well fitting 
and parsimonious model that confirms the two-factorial structure of the CAINS. There were no 
cross-loadings of  CAINS-MAP items to the CAINS-EXP subscale and vice versa. Hence, the 
individual items are specific for their respective scales. The loadings of  items 10 to 13 on the 
“expression” subscale are both high and reliable. However, there is some concern with some 
items of  the “motivation and pleasure” subscale. The lower bound of  the item loadings’ 
confidence intervals is below 0.3 for items 1, 5 and 6. These items tap motivation for family 
relationships as well as motivation for and expectation of  pleasure at work and/or school, 
respectively. The original validation study’s exploratory factor analysis found factor loadings of  
0.33 for item 1 (there: 1. social: family relationships), of  0.24 for item 5 (there: 6. vocational: 
motivation) and of  0.39 for item 6 (there 8. vocational: expected pleasure). Those three items 
were in the bottom four of  factor loadings (Kring et al., 2013). Substantial conceptual overlap 
between some CAINS-MAP items was not unexpected. Relevant overlap was found for items 5 
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and 6 which inquire motivation for and expectation of  pleasure at work and/or school, for items 
3 and 4 which appraise past-week and expected pleasure concerning social activities as well as for 
items 4 and 9 which assess expected pleasure in regard to social and leisure activities, respectively. 
We consider all CAINS item contents important, however, to further establish the relevance and 
validity of  the specific items of  the “amotivation" factor, further analysis of  a larger sample 
would be interesting. A first step could be exploratory factor analysis to determine, whether 
Ahmed et al. (2018)’s hierarchical 5-factorial model of  the BNSS also holds true for the CAINS. 
It should be noted, however, that partly the two-factorial solution could be explained by 
common-method variance: CAINS-MAP mainly assesses verbal report of  experience; CAINS-
EXP is a rating of  within-interview behavior. 
4.3 Validity Assessment 
With the two-factorial structure of  the CAINS adequately established, a nuanced 
discussion of  the validity assessment is warranted. Overall, there seem to be distinct correlational 
profiles for the two subscales; this further substantiates them measuring different aspects of 
negative symptoms. The “expression” subscale might be less impacted by secondary negative 
symptoms (Farreny, Savill, & Priebe, 2018). The “motivation and pleasure" scale has more 
positive associations with related domains than the “expression” subscale. This mirrors the more 
advanced theoretical models for the “amotivation” subdomain (Kaiser et al., 2017). Both 
subscales correlate well with the PANSS Marder Negative score and moderately (CAINS-EXP) 
to strongly (CAINS-MAP) with social competence. For the “expression" domain, Marder and 
Galderisi (2017) suggested that abnormal functioning of  the mirror neuron system could explain 
deficits of  1) social perception and 2) motor activity which might affect social competence. 
Fittingly, Riehle, Mehl, and Lincoln (2018) found significantly fewer positive facial expressions in 
subjects with schizophrenia with predominantly expressive deficits than in those without as well 
as in controls; the former were also rated significantly lower on social performance skills assessed 
by role-play. Furthermore, it is highly likely for assessments derived from behavioral observation 
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– i.e. both in interview and role-play – to overlap. For the “motivation and pleasure" domain, 
poor social cognition seems linked to asociality/social withdrawal, although the direction of  that 
link is unclear up to now (e.g. Marder & Galderisi, 2017). Blanchard, Park, Catalano, and Bennett 
(2015) also found strong associations for CAINS-MAP symptoms with performance-based 
affiliative skills (i.e. responding to a video) as well as role-play; this could point to an influence of  
social amotivation. We think those aspects could partially explain the observed association of  
social competence and both CAINS-MAP and CAINS-EXP. The self  assessed anticipatory 
anhedonia (TEPS-ANT) correlates moderately with the CAINS-MAP. Anticipatory anhedonia 
was consistently found to be associated with motivational processes specific to the “amotivation” 
domain of  negative symptoms (Gard et al., 2007). Functional outcome consistently is linked 
more strongly to amotivation than expressive deficits (Marder & Galderisi, 2017); we also found 
this in our data. The CAINS’ “motivation and pleasure” subscale has a significant but smaller 
than expected correlation with the very meticulously measured level of  activity (Time Budget 
Measure). This probably is due to the CAINS-MAP focusing on inner experience as opposed to 
mainly assessing behavior. Experience sampling depends on the symptoms being accessible, 
identifiable and reportable for the patient. When using more behavior-based assessments, 
however, confounding symptoms and outcome is a significant issue. Correctly identifying the 
origin of  symptoms (primary, secondary) is difficult for assessments based on self-report as well 
as performance-based measures. Assessing “true amotivation” will probably remain difficult and 
will need assessment from more than one perspective (i.a. to rule out confounding aspects). 
Maybe a compound score of  performance assessment, experience sampling, and self-report 
could achieve this aim. 
In qualification it should be noted, that the validity sample V consisted of  outpatients 
with relevant negative symptoms, whereas depressive symptoms had to be below “severe”. Also, 
our sample showed a very low rate of  extrapyramidal symptoms. The subjects often were 
assessed shortly after hospital discharge; this is a phase of  illness associated with less positive and 
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more depressive symptoms (Peralta et al., 2000). Overall, there are high comorbidity rates for 
schizophrenia and unipolar depression across stage and state of illness (Upthegrove, Marwaha, & 
Birchwood, 2017). Even though we excluded severely depressed patients, the “motivation and 
pleasure” subscale is weakly linked to positive and depressive symptoms. The latter could be due 
to conceptual overlap of depressive and negative symptoms. Mainly the “avolition” factor entails 
symptoms that are also main symptoms of depression: loss of interest, anhedonia, and reduced 
energy. For schizophrenia patients and the CAINS or its “motivation and pleasure” subscale’s 
self rating MAP-SR, some researchers found no significant associations with measures of 
depression (Engel et al., 2014; Kring et al., 2013; Llerena et al., 2013) while others found a weak 
to moderate correlations (Engel & Lincoln, 2016; Park et al., 2012). Shared method variance 
could also play a part in the overlap of  mainly “amotivation” and positive and depressive 
symptoms. 
We found no significant association of  our global index of  neurocognition and CAINS-
EXP and a moderate correlation for the CAINS-MAP. Marder’s 2017 review reports amotivation 
to be linked to deficits in abstraction/flexibility and executive functioning – deficits in executive 
functions probably impair action planning and lead to apathy. Strauss, Morra, Sullivan, and Gold 
(2015) found low cognitive effort to be associated with severe negative symptoms; both predicted 
global neurocognitive impairment. However, diminished expression usually correlates with 
impaired overall cognitive performance (Hartmann-Riemer et al., 2015). A. S. Cohen, Mitchell, 
and Elvevåg (2014) proposed a cognitive resources limitation model with speech reduction as 
reaction to cognitive overload, hence a specific relationship of  alogia and verbal fluency. Overall, 
our neurocognitive index seems too global to clarify the complex association between cognitive 
dysfunction and the two factors of  negative symptoms. 
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4.4 Conclusion 
To relevantly improve negative symptoms, we need to 1) increase our understanding of 
the symptom complex, 2) develop specific treatment strategies aiming at different aspects of 
negative symptoms, and 3) precisely assess these interventions. We consider the CAINS to be 
overall well suited to promote these purposes. We would recommend against solely using the 
composite CAINS score, but to take into account both CAINS subscales separately. Researchers 
interested in utilizing the results of  our CFA more specifically could use the following formulas 
to compute the CAINS subscales: CAINS-MAP = (0.33 × item 1 + 0.51 × item 2 + 0.58 × item 
3 + 0.53 × item 4 + 0.39 × item 5 + 0 .24 × item 6 + 0.85 × item 7 + 0.89 × item 8 + 0.74 × 
item 9) ÷ 9; CAINS-EXP = (0.81 × item 10 + 0.92 × item 11 + 0.72 × item 12 + 0.69 × item 
13) ÷ 4. Since there are only four CAINS-EXP items to nine CAINS-MAP items, the motivation 
aspect is overrepresented in the total score. Moreover, we think the CAINS-MAP subscale might 
benefit from more research clarifying the individual items’ specific subdomains, importance for 
the subscale, and stability as well as discriminant validity with depression. Overall, the two 
subscales clearly and mostly reliably measure distinct aspects of  negative symptoms; we think the 
research on negative symptoms could benefit from consistently taking note of  both. 
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Abstract 
The negative symptom domain remains a major challenge concerning treatment. A valid 
self-report measure could assist clinicians and researchers in identifying patients with a relevant 
subjective burden. The Motivation and Pleasure - Self Report (MAP-SR) derives from the 
CAINS and is supposed to reflect the “amotivation” factor of negative symptoms. We evaluated 
different aspects of the scale's reliability and validity. This is the first factorial analysis as well as 
the first analysis of test-retest reliability. We assessed three samples of subjects with 
schizophrenia or schizoaffective disorder (n = 93) and a broad spectrum of related domains. We 
explored a 3-, 2- and 1-factor solution (explaining 50.93, 44.85 and 36.18% of variance, 
respectively). The factor “pleasure and hedonic activity” consists of eight items and was most 
robust; the factors “social motivation” and “motivation for work” were problematic. Test-retest 
reliability of the scale was adequate (rS = 0.63, p = .005). Neither the MAP-SR nor the “pleasure 
and hedonic activities” factor are associated with the PANSS negative symptom scale. There are 
significant associations with the observer-rated CAINS-MAP scale, experiences of pleasure, and 
social cognition but none with functional outcome. Discriminant validity could not be established 
with regards to depression and extrapyramidal symptoms. We found that the MAP-SR is 
adequate to assess anhedonia but is less suitable when assessing motivation. Therefore, we 
propose using the “pleasure and hedonic activity scale” to cover the “anhedonia” sub domain. 
We think the “motivation” part of the instrument requires reconstruction. 
 
1. Introduction 
Negative symptoms remain a major challenge in the treatment of schizophrenia (Fusar-
Poli et al., 2015). It seems critically important to further our understanding of the symptom 
complex, try to develop specific treatment strategies for different aspects of negative symptoms, 
and precisely assess these treatments. To establish negative symptoms as primary endpoint in 
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treatment studies, clear operationalization and construct validation of measuring instruments is 
needed (e.g. Marder & Galderisi, 2017). 
The first factorial conceptualization of negative symptoms comprised emotional blunting, 
alogia, avolition, anhedonia, social withdrawal and attention deficits (Andreasen, 1982). Most 
diagnostic instruments aiming to measure negative symptoms inquire these symptom domains. 
However, recent studies on the factorial structure of negative symptoms suggest that some of the 
subdomains overlap, while others can be distinguished from each other. Overall, the models 
converge towards a two-factorial structure with a) “diminished expression” which covers 
emotional blunting and alogia and b) “amotivation” which contains avolition, anhedonia and 
social withdrawal. Inappropriate affect, poverty of content of speech, and reduced attention load 
on a third factor which isn’t considered part of the negative symptom domain anymore and 
seems to correspond to cognitive dysfunction and disorganization. “Diminished expression” and 
“amotivation” correlate moderately (0.47 - 0.57) (e.g. Marder & Galderisi, 2017). A recent 
factorial analysis of Ahmed et al. (2018) found a hierarchical 5-factor model for the Brief 
Negative Symptom Scale (BNSS) with two second-order factors reflecting “expression” and 
“amotivation” as well as 5 first-order factors reflecting blunted affect, alogia, anhedonia, 
avolition, and asociality. The factors might respond differently to treatment (e.g. Kaiser et al., 
2017; Riehle, Pillny, & Lincoln, 2017): for instance, amotivation seems to improve more with 
CBT and social skills training, blunted affect with nonverbal treatments (i.e. body-oriented 
psychotherapy). 
The National Institute of Mental Health consensus document (Kirkpatrick, Fenton, 
Carpenter, & Marder, 2006) called for the development of rationally constructed scales that refer 
to the two-factorial structure of negative symptoms. Subsequently, the BNSS (Kirkpatrick et al., 
2011) and the Clinical Assessment Interview for Negative Symptoms (CAINS, Kring, Gur, 
Blanchard, Horan, and Reise (2013)) were developed with this in mind. Both measures have good 
internal consistency, convergent validity, and discriminant validity (Strauss & Gold, 2016). The 
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CAINS consists of two scales: the “motivation and pleasure” scale (CAINS-MAP) strives to 
measure attitudes, intrinsic motivation and subjective experience of pleasure, the “expression” 
subscale (CAINS-EXP) asks the rater to assess vocal prosody, gestures, facial expression and 
quantity of speech (Kring et al., 2013). 
Interestingly, there are only few established self-rating measures in the field of psychosis – 
the majority of endpoints in clinical studies are derived from interview-based rating scales. 
However, there are findings indicating that patients with schizophrenia can adequately assess at 
least parts of the negative symptom complex (Dollfus, Mach, & Morello, 2016; Lincoln, Dollfus, 
& Lyne, 2017; Llerena et al., 2013). A valid self-report measure could assess subjective aspects of 
negative symptoms and assist clinicians and researchers in time-savingly identifying patients with 
a relevant subjective burden. Furthermore, it could enable online research and large scale panel 
studies with community samples. 
As far as we are aware, there are only three specific self-rating negative symptom 
measures (Lincoln et al., 2017): the Subjective Experience of Negative Symptoms (SENS, Selten, 
Sijben, van den Bosch, Omloo-Visser, and Warmerdam (1993)), the Self-Evaluation of Negative 
Symptoms (SNS, Dollfus et al. (2016)), and the Motivation and Pleasure - Self Report (MAP-SR, 
Llerena et al. (2013)). The SENS derives from the SANS and is interview-based. Thus, it is quite 
time-consuming, might be influenced by the interviewer, and also includes items outside the 
amotivation and expression domains. So far, there is no data on its convergent or discriminant 
validity. The SNS could be the most up-to-date instrument, since it evaluates emotional range 
and alogia as well as amotivation and thus covers the five domains of negative symptoms. Factor 
analysis extracted two factors (“apathy” and “emotional”) that accounted for 75.2% of the 
variance, but did not clearly differentiate amotivation and expression. Furthermore, its 
convergent as well as discriminant validity have not yet been evaluated comprehensively. The 
MAP-SR derives from the “motivation and pleasure” subscale of the CAINS and was developed 
as a self-rating instrument for avolition in schizophrenia. Its precursor, the Clinical Assessment 
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Interview for Negative Symptoms – Self Report (CAINS-SR, Park et al. (2012)) also tried to 
assess expressive deficits but found poor psychometric properties for this subscale. They 
concluded that self-reports of negative symptoms should focus on the experiential domain. Six of 
the MAP-SR’s items tap social pleasure, recreational pleasure and work pleasure, six feelings and 
motivations about close, caring relationships, and six motivation and effort to engage in activities 
(social, recreational and occupational). Looking at the usual procedure in validating new 
measures, the MAP-SR is still at an early stage. For the original version of the scale, Llerena et al. 
(2013) found good internal consistency (Cronbach’s α = 0.9) after a scale reduction (18 to 15 
items, n = 37). Convergent validity to the “motivation and pleasure” scale of the CAINS (r = 
0.65), social anhedonia (r = 0.48) and social engagement (r = 0.57) was established. No significant 
correlations were found for positive symptoms and depression/anxiety as well as general 
cognitive abilities signifying adequate discriminant validity. Further validation studies were 
undertaken by Engel and Lincoln (2016) for the German version of the MAP-SR (n = 50) and 
Kim et al. (2016) for the Korean MAP-SR (n = 137). Both found good internal consistency, 
strong to moderate convergent validity regarding correlations to the “motivation and pleasure” 
scale of the CAINS as well as other measures for negative symptoms. No significant correlation 
with the “expression” subscale of the CAINS was observed in the German study (Engel & 
Lincoln, 2016), whereas a weak correlation was observed in the Korean study (Kim et al., 2016). 
This partially supports the distinction between these subdomains; however, Engel and Lincoln 
(2016) discussed a possible lack of commonality between the avolition and expression aspects of 
negative symptoms. Discriminant validity was established finding no significant correlation with 
positive symptoms and rater-assessed depression/anxiety; Kim et al. (2016) also found no 
significant link to neurocognition. Engel and Lincoln (2016) found a moderate but significant 
correlation with the BDI-II. The authors of previous validations called for investigation of 
temporal stability (Engel & Lincoln, 2016; Llerena et al., 2013). The MAP-SR was constructed to 
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represent the “amotivation” factor of negative symptoms, so far there was no empirical analysis 
of its factorial structure. 
The objective of this paper is to evaluate the German version of the MAP-SR regarding 
factorial structure, validity, and reliability. 
 
2. Methods 
2.1 Participants 
Three independently collected samples were used: a “convergent and discriminant 
validity” sample (sample V), a “test-retest and interrater reliability” sample (sample R) and an 
additional sample to increase the sample size of the pooled “exploratory factor analysis” sample 
(EFA sample). Inclusion criteria across all samples were diagnosis of a psychotic disorder 
according to DSM-IV, age 18 to 65 years, sufficient German language skills, normal or corrected 
to normal vision and hearing as well as capability to give consent. Exclusion criteria were 
substance dependence as the leading clinical problem and intellectual disability (IQ < 70, 
approximated by level of education). In addition to these common inclusion and exclusion 
criteria, there were sample-specific differences.  
Sample V was used to assess the MAP-SR’s convergent and discriminant validity and 
included 55 outpatients in a stable phase. Since sample V was the baseline examination of a study 
that aimed to improve negative symptoms using individual and group CBT, the participants had 
to have relevant negative symptoms (PANSS items N1 to N4, N6, G7 und G16 ≥ 10) and to be 
in outpatient treatment to be included. Sample V’s additional exclusion criteria were severe 
depressive symptoms (PANSS, G6 > 4), structural brain lesions, severe extrapyramidal side 
effects (Modified Simpson-Angus Rating Scale (MSAS) > 11), and current psychotherapeutic 
treatment. The diagnosis of a psychotic disorder according to DSM-IV was established using the 
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Structured Clinical Interview for DSM-IV (SCID-I) for sample V. Sample V’s participants 
received a monetary compensation for their assessment, the other samples did not. 
Sample R was primarily used to assess the scale’s interrater- and test-retest reliability and 
comprised 25 patients in the stabilization phase; 19 of whom were still available for the second 
assessment. In sample R, further assessment was videotaped, so the participants had to agree to 
this. 
The additional sample comprised 15 inpatients and outpatients used to increase the 
cumulated sample size for the EFA. Sample R and the additional sample were diagnosed with the 
German Brief Diagnostic Interview of Mental Disorders (Mini-DIPS). 
Both sample V and R as well as the additional sample (n = 93 because two subjects 
partook in sample V and R) were used for exploratory factorial analysis and to assess the internal 
consistency of the measure. The samples were also used to further assess the CAINS; publication 
is planned. Demographic and clinical characteristics of the samples can be found in table 3-1. 
Table 3-1 
 
Notes. PANSS = Positive and Negative Syndrome Scale; CDSS = Calgary Depression Scale for Schizophrenia; PSP = 
Personal and Social Performance Scale. 
Demographics of SampleV, Sample R and the EFA-Sample
Sample V (n=55) Sample R (n=19) EFA-Sample (n=93)
Age (yrs) 40.56 (10.96) 36.26 (10.86) 38.99 (10.99)
Male (%) 67.3 53 66.7
Age at 1st hospitalization (yrs) 25.55   (8.70) 22.78   (7.22) 25.33   (8.08)
Diagnosis (%)
  Schizophrenia 85.5 74 85
  Schizoaffective disorder 14.5 26 15
PANSS Total score 64.38 (12.42) 64.26 (22.41) 64.83 (15.63) (n=81)
CDSS Total score   3.67   (3.79)
PSP 59.27 (13.34)
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2.2 Procedures and Measures 
The study protocol was approved by the ethics committee of the University of 
Tuebingen’s medical faculty. After giving informed consent, all screened participants that met 
inclusion criteria were interviewed using the following measures: 1) a structured interview to 
obtain basic demographic data, 2) the MAP-SR, 3) the PANSS (30-item clinician-rated measure 
of psychosis symptoms, scored 1 (absent) to 7 (extreme); Cronbach’s α = .74 to .83) as well as 4) 
the CAINS (13-item semi-structured interview scored 0 (no impairment) to 4 (severe deficit), 
Cronbach’s α = .76). 
Sample V’s assessment took approximately four hours and included the following 
additional measures: 1) the Time Budget Measure (TBM; 28-item semi-structured interview, 
scored 0 (nothing) to 4 (variety of demanding independent activities)) whose structured 
retrospective assessment of the past week is intended to reflect the actual level of activity, 2) the 
Calgary Depression Scale for Schizophrenia (CDSS; nine-item structured interview of depressive 
symptoms in schizophrenia scored 0 (absence) to 3 (highest severity); Cronbach’s α = .79), 3) the 
Personal and Social Performance Scale (PSP; 100-point single-item rating scale) as a rating of 
psychosocial functioning as well as 4) the Modified Simpson-Angus Scale (MSAS; 10 items 
scored 0 (normal) to 4 (severe); Cronbach’s α = .79) assessing extrapyramidal side effects. 
Additionally, there was a performance assessment of social skills using role play, the Social Skills 
Performance Assessment (SSPA; two 3-min role-plays (greeting a new neighbor and lodging a 
complaint with the landlord); performance scored 1 (poor) to 5 (excellent)), which was audio 
recorded. Furthermore, we assessed cognitive functioning employing 1) the Trail Making Test A 
and B (TMT-A, TMT-B), 2) the German version of the auditory verbal learning test (VLMT), 3) 
the Tower of London (ToL) as well as 4) the Wechsler Adult Intelligence Scale‘s Digit Span task 
(WAIS-IV-DS). Lastly, the participants were asked to fill in additional questionnaires: 1) the 
Frankfurt Self-Concept Scales (FSKN; 48 items scored 1 (I strongly agree) to 6 (I strongly 
disagree); Cronbach’s α = .93 to. .97), assessing components of self-concept including the 
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subscale “appreciation by others” (FSWA) as a measure of social cognition and 2) the Temporal 
Experience of Pleasure Scale (TEPS; ten items assessing anticipatory, eight consummatory 
pleasure scored 1 (very false for me) to 6 (very true for me); Cronbach’s α .71 to .79). 
Sample R’s initial assessment lasted approximately one hour during which the CAINS 
interview was videotaped. 14 (+/- 5) days after the first assessment, participants were evaluated 
again, which took about 25 minutes. 
The additional sample’s assessment included further measures and took approximately 1.5 
hours. 
The German versions of the CAINS and TEPS were kindly made available to us by the 
research group led by Tania Lincoln, Department of Clinical Psychology and Psychotherapy, 
University of Hamburg. The English versions of the MAP-SR, TBM and SSPA were translated 
into German by our research group and retranslated by an English native speaker. Differences to 
the original English versions were discussed among the translators and a consensus was agreed 
on. 
2.3 Data Analysis 
Using SPSS 25.0, we first assessed 1) the MAP-SRs factorial structure, 2) internal 
consistency including item-level descriptives “α if item deleted”, 3) stability of items using test-
retest correlations as well as 4) the items’ convergent validity with corresponding CAINS items. 
We tested for normal distribution and homoscedasticity. Pearson or Spearman correlations 
respectively were used for these correlational analysis and we used Holm-Bonferroni sequential 
correction to deal with the multiple testing problem. For demographic data a rate of missings ≤ 
10% was not reported. When calculating the scale composites, up to 5% and 10% missing values 
for assessments and self-ratings respectively were replaced by the scale’s mean. Measures with 
more missing data were excluded from the analysis. 
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The EFA sample (n = 93) was used for the exploratory factor analysis. Kass and Tinsley 
(1979) recommend ≥ 5 participants per variable (here: 15 items, n ≥ 75); therefor our sample size 
(n = 93) could be adequate. According to Fabrigar, Wegener, MacCallum, and Strahan (1999) 
communalities > 0.6 suggest a sample size < 100 may be adequate. The communalities of items 
3, 6,7, 8, 9 and 13 are < 0.6, > 0.20. Kolmogorov-Smirnov tests indicated non-normally 
distributed data, but skewness and kurtosis values were all < |2| and < 7 respectively. Visual 
inspection of inter-item scatter plots suggests sufficient linearity. There were two multivariate 
outliers identified via Mahalanobis distance at α = 0.001 and 11 at α = 0.05; there was no 
theoretical justification for the exclusion of any outliers. The KMO measure of sampling 
adequacy was 0.80 suggesting ‘great’ common variance for factor analysis. The diagonals of the 
anti-image correlation matrix (Measures of Sampling Adequacy) were all > 0.5. Bartlett’s test of 
sphericity was significant (χ2 (105) = 618.64; p < .001), pointing to large enough item correlations 
for analysis. Concerning multicollinearity, tolerance values were well above 0.10, VIFs < 3.7. 
However, the determinant of the correlation matrix as well as Haitovsky's test suggest 
multicollinearity. The greatest inter-item correlation was 0.81 for items 4 and 5; we do not 
consider this high enough for elimination. Hence, the possible multicollinearity is a limitation of 
the statistic method. 
Initial analysis yielded four eigenvalues > 1 (Kaiser Criterion), explaining 66.99% of the 
variance; 40.23% thereof explained by factor 1, 10.44 by factor 2, and 8.40% by factor 3. The 
scree plot can be found in figure 3-1. Verlicers’ Minimum-Average-Partial-Test (1976) suggests 
one, the 2000-version three factors for extraction. The theoretical framework for the scales’ initial 
construction suggests one factor - supposedly the “amotivation” or ”motivation and pleasure" 
factor of negative symptoms. Ahmed et.al (2018)’s hierarchical model of negative symptoms 
found three sub factors for amotivation: anhedonia, asociality and avolition. We decided to 
present the 1-, 2-, and 3-factor-solution to see how the MAP-SR fits with those considerations. 
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Figure 3-1. Scree plot of the exploratory factor analysis. 
 
The maximum likelihood method is thought to be adequately robust given the 
preconditions (e.g. Chou & Bentler, 1995). We performed a maximum likelihood factor analysis 
for one, two and three factors (the two latter with oblique rotation (direct oblimin)). Stevens (2002) 
suggests 0.57 as critical value for relevant loadings in sample sizes around 80 and 0.51 for a 
sample size of 100. Guadagnoli and Velicer (1988) consider factors with four or more loadings > 
0.6 reliable regardless of sample size. We decided to consider loadings ≥ .55 adequately reliable. 
Pearson or Spearman correlations respectively were used to evaluate convergent and 
discriminant validity of the scale and found subscales. Since we consider this part of the analysis 
exploratory, we did not account for multiple testing. 
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3. Results 
3.1 Scale Construction/Item Analysis 
3.1.1 Factorial Validity 
Table 3-2 highlights the loadings of the 1-, 2- and 3-factor-solutions as well as the 
percentage of explained variance for each factor (EFA sample, n = 93). The 3-factor-version 
explains 50.93% of the variation, the 2-factor 44.85% and the 1-factor-solution 36.18%. The 
factors of the 2-factor solution correlated with r = -0.41. For the 3-factor solution, “pleasure and 
hedonic activity” and “social motivation” correlated with r = 0.32, “pleasure and hedonic 
activity” and “motivation for work” with r = 0.37, and “social motivation” and “motivation for 
work” with r = 0.45. 
3.1.2 Internal Consistency of the MAP-SR and Subscales 
Cronbach’s α for the MAP-SR was 0.87 (EFA sample, n = 81) with no relevant gain in 
discarding any item (no “α if item deleted” > 0.88). 
For the subscale “pleasure and hedonic activity” (items 1 to 6, 14 and 15) Cronbach’s α 
was 0.89 (n = 91) with no “α if item deleted” > 0.88, for “social motivation” (items 10 and 11; n 
= 93) 0.86 and for “motivation for work” (items 12 and 13; n = 91) 0.82. 
3.1.3 Stability 
Table 3-3 shows sub-sample R’s test-retest reliability correlations (n = 19) for the items as 
well as the MAP-SR composite score (rS = 0.63, p = .005). The subscales “pleasure and hedonic 
activity” had a test-retest reliability of r = 0.57, p = .011, “social motivation” of r = 0.03, p = .906, 
and “motivation for work” of rS = 0.75, p < .001. 
3.1.4 Correlation with Corresponding CAINS Items/Constructs 
The correlations with corresponding CAINS items or constructs can be found in table 3-
3 (EFA sample, n = 93).  
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3.1.5 Missings 
Analysis of data showed 10.8% of item 8 missing; all other items were missing ≤ 2.2%; 
see table 3-3 (EFA sample, n = 93). 
Table 3-3 
 
Note. † = possibly inadequate question. Holm-Bonferroni Sequential Correction was used for correlations per 
columns excluding the MAP-SR total score. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. Bold: factor loadings ≥ .55. 
a =  CAINS item 3: past week social pleasure; b = CAINS item 4: expected social pleasure; c = CAINS item 8: past 
week pleasure from hobbies; d = mean of CAINS items 6&9: expected pleasure work, school&hobbies; e = CAINS 
item 1: family relationships; f = CAINS item 2: friendships; g = mean of CAINS items 1&2: family 
relationships&friendships; h = CAINS item 5: motivation for work&school; i = 7: motivation for hobbies. 
3.2 Convergent and Discriminant Validity of the MAP-SR 
Table 3-4 shows the MAP-SR’s as well as the subscales “pleasure and hedonic activity” 
“social motivation” and “motivation for work”’s convergent and discriminant validity (sample V, 
n = 55).  
Relevant Results of Item Analysis
Item Factor Loadings '1'
Factor 
Loadings '2'
Factor 
Loadings '3' Stability CAINS-MAP Missings Item Domain
1 .69 Factor 1: .77 Factor 1: .74 .38    -.30*   a -.34*  1.1 Pleasure: Social
2 .70 Factor 1: .77 Factor 1: .72 .64*  -.36*** a -.33*  1.1 Pleasure: Social
3 .64 Factor 1: .68 Factor 1: .65 .54*  -.26     b -.23  2.2 Pleasure: Social
4 .80 Factor 1: .75 Factor 1: .80 .55    -.16     c -.22      .0 Pleasure: Hobbies&Work
5 .83 Factor 1: .80 Factor 1: .86 .29    -.19     c -.21      .0 Pleasure: Hobbies&Work
6 .67 Factor 1: .64 Factor 1: .67 .78*** -.18    d -.17   1.1 Pleasure: Hobbies&Work
7 .24 Factor 1: .28 Factor 1: .26 .06    -.45*** e -.34*     .0 Motivation: Family
8† .29 Factor 1: .31 Factor 1: .28 .89*** -.29     f -.14   10.8 Motivation: Partner
9 .50 Factor 1: .47 Factor 1: .44 .48    -.26     f -.15   1.1 Motivation: Friends
10 .53 Factor 2: -.97 Factor 2: .99 .00    -.02     g -.05      .0 Motivation: Social
11 .51 Factor 2: -.77 Factor 2: .76 .00    -.09     g -.11      .0 Motivation: Social
12 .52 Factor 1: .49 Factor 3: .90 .66*  -.38*** h -.22   2.2 Motivation: Work
13 .47 Factor 1: .48 Factor 3: .83 .58    -.42*** h -.18   1.1 Motivation: Work
14 .67 Factor 1: .63 Factor 1: .62 .49    -.27     i -.26      .0 Motivation: Hobbies
15 .63 Factor 1: .59 Factor 1: .58 .00    -.26     i -.21      .0 Motivation: Hobbies
MAP-SR .63**  -.35** 1.1
CAINS items
/constructs
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4. Discussion 
This is a comprehensive analysis of the psychometric properties of the MAP-SR and its 
items. The sample size met methodological requirements for analysis. We assessed a broad 
spectrum of related domains and – to our knowledge – this is the first factorial analysis as well as 
the first analysis of test-retest reliability. 
4.1 Item Analysis and Scale Construction  
Concerning the items, the six MAP-SR items designed to tap “pleasure” seem to be 
robust: with reliable factor loadings on all factor solutions, hinting at adequate test-retest 
reliability and convergent validity and with no relevant missing data. For the nine-item 
“motivation”-part of the scale, there are less sound findings. For the 1-factor-solution, there are 
two relevant item loadings assessing motivation for hobbies (i.e. hedonic activities which seems 
close to the pleasure construct) with no significant test-retest correlations as well as no significant 
correlation with corresponding CAINS items/constructs. For the 2- and 3-factor-solutions, the 
items tapping motivation for social activities load on a common factor but show less than 
satisfactory item stability and convergent validity. The items assessing motivation for work 
constitute one factor of the 3-factor-solution, show good convergent validity with CAINS 
items/constructs as well as sufficient stability. Three items (7, 8 and 9) do not load reliably on any 
of the factors. Item 9 does not correspond significantly to the CAINS as well. Item 7 
corresponds well to the CAINS and has no missings but is not stable over time. Item 8 has good 
test-retest reliability but a lot of missing data – presumably because it asks about partners and 
could be difficult to answer for those participants not in a romantic relationship. 
The MAP-SR set out to represent one of the two subdomains of negative symptoms, the 
„amotivation“ factor. The 1-factor-solution, however, mainly seems to encompass items designed 
to measure pleasure or anhedonia. The results of the factorial analysis could be interpreted in 
light of a recent factorial analysis on the rater-assessed Brief Negative Symptom Scale: Ahmed et 
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al. (2018) found the best fit for two second-order factors reflecting “expression” and 
“amotivation” as well as 5 first-order factors reflecting blunted affect and alogia as well as 
anhedonia, avolition and asociality. For the three-factor-solution Ahmed et al. (2018)’s anhedonia 
could overlap with our “pleasure and hedonic activity”, their avolition with our “motivation for 
work” and asociality with our “social motivation”. It should be kept in mind, however, that both 
additional factors only consist of two items, and that those items with rather poor stability and 
relatively low factor loadings have the greatest loadings on the “pleasure and hedonic activities” 
factor. 
Concerning test-retest reliability, the MAP-SR as well as the “pleasure and hedonic 
activities” and “motivation for work” factor seem promising. It should be kept in mind that our 
sample R is small (n = 19), and featured in-patients in the stabilization phase. 
Overall, we think of the three factors the “pleasure and hedonic activities” factor shows 
the most promise. Thus, we will discuss the MAP-SR in its entirety and this factor with regards to 
convergent and discriminant validity. 
4.2 Validity Analysis 
There are interesting results for the validity analysis. Concerning convergent validity, 
neither the MAP-SR nor the “pleasure and hedonic activities” factor are associated with the 
PANSS negative symptom scale. It has to be stated, however, that there is criticism on this 
specific PANSS scale: its seven items include “abstract thinking” and “stereotyped thinking”; 
both are not considered part of the negative symptom domain anymore. There are significant 
associations with the observer-rated CAINS-MAP scale, the TEPS (sampling experiences of 
pleasure) and social cognition but none with functional outcome. This might point to a possible 
benefit of the instrument: It could measure aspects of the negative symptom domain, which 
might not be picked up reliably by the observer ratings, namely the area that is far from 
functional outcome but close to subjective experience: e.g. inner need for 
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company/engagement/activities vs. mere attendance, experienced pleasure vs. observed 
expression of emotion. It should be mentioned, though, that there could be some common-
method bias, since mainly the other self-rating instruments correlate highly. 
Furthermore, there is evidence for overestimation by patients and/or underestimation by 
therapists when assessing e.g. quality of life (rated more poorly by mental health workers than 
their clients (Ofir-Eyal, Hasson-Ohayon, Bar-Kalifa, Kravetz, & Lysaker, 2017)) or medication 
side effects (reported more frequently and rated more severe by patients than clinicians 
(Lindström et al., 2001)). With regard to functional status, Bowie et al. (2007) compared 
underestimating, accurate and overestimating patients. Underestimators performed better 
cognitively and reported more depressive symptoms than overestimators. Accurate raters had 
better social skills than both other groups. Overestimators were most cognitively and functionally 
impaired. Over-/underestimation also could play a role when reporting or observing negative 
symptoms; this may be moderated by factors such as depression, positive symptoms, cognitive 
functioning, and insight. Selten, Wiersma, and van den Bosch (2000) looked for predictors for 
discrepancy between patients and psychiatrists concerning negative symptoms. They found that 
depression impacts discrepancy scores negatively and anxiety positively; there was no association 
for insight into positive symptoms. Even still, small-scale studies show that patients can correctly 
self-assess some symptoms of psychosis: Liraud, Droulout, Parrot, and Verdoux (2004) found 
this for individual positive and negative symptoms, except for persecutory delusion and alogia. 
Hamera, Schneider, Potocky, and Casebeer (1996) report that self-report of positive and 
nonpsychotic symptoms may be more congruent to rater assessment than self-report of negative 
or deficit symptoms; however, those were only assessed with two items, i.e. emotional withdrawal 
and motor retardation. Considering all known rater biases in clinical assessments (Hoyt, 2000), it 
seems sensible to complement them with self-reports. We consider this even more important in 
this specific area of research: In patients with difficulties in expressing emotions, self-reports 
could reflect the inner experience of patients more validly. 
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Concerning discriminant validity there are problems with regards to depression and 
extrapyramidal symptoms. The validity sample V comprised outpatients with relevant negative 
symptoms, but with depressive symptoms below “severe”. There was a very low rate of 
extrapyramidal symptoms; hence correlation of the MAP-SR and of the “pleasure and hedonic 
activity” factor and the measure of extrapyramidal symptoms could be due to the low variance in 
the latter measure. The correlation of the MAP-SR, the “pleasure and hedonic activity” factor 
and the “social motivation” factor with the CDSS could also be due to the fact that depression 
and mainly the “amotivation” factor of negative symptoms overlap (loss of interest, anhedonia, 
and reduced energy) and thus are not trivial to differentiate. In their validation study of the 
German MAP-SR Engel and Lincoln (2016) also found significant correlations with the BDI-II; 
they contemplated problems in differentiating negative and depressive symptoms when 
exclusively self-report are utilized. Papsuev, Movina, Minyaycheva, and Luther (2017) investigated 
the association between self-rated and clinician-rated motivation, and (i.a.) depression. They also 
found correlations for self-rated motivational deficits and observer-rated depression and 
speculate that patients could be less aware of primary negative symptoms, and instead rate 
secondary negative symptoms caused by depression. 
4.5 Conclusion 
There are only few self-rated specific negative symptom measures, the MAP-SR being 
one of them. Other authors already mentioned shortcomings like absence of an expression 
subscale (thus no coverage of alogia and affective blunting) as well as the challenge to self-
evaluate consummatory and anticipatory pleasure (Lincoln et al., 2017). We found that the MAP-
SR is adequate to assess anhedonia but is less suitable when assessing motivation. Therefore, we 
propose to use items 1 to 6 and item 14 and 15 as a “pleasure and hedonic activity scale” 
covering the “anhedonia” sub domain of the “amotivation” factor of negative symptoms. We 
think the “motivation” part of the instrument requires reconstruction. It might benefit from new 
and more items covering different aspects of motivation. Motivation for social relations and 
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motivation/drive for (work) activities could be surveyed more in detail and might benefit from 
more straightforward questions. They could try to cover Ahmed et al. (2018)’s “asociality” and 
“avolition”. Pointers to possible item content could be taken from the CAINS’ and the BNSS’ 
related items and their probe questions. For “sociability” in addition to the two items assessing 
motivation to be around others and effort to do things with others, the amount and intensity of 
contact with family and friends, who mainly initiated contact, feelings of closeness to other 
people and desire for contact could be inquired. For “avolition” items assessing the amount of 
time spent doing something vs doing nothing and personal initiative and perseverance when 
doing projects, could complement the two items inquiring motivation for and effort to do things 
at work or school. The validity and reliability of this resulting scale should be evaluated in further 
studies. 
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Abstract 
There is conceptual overlap between negative and depressive symptoms: Mainly the 
‘avolition’ factor of negative symptoms also encompasses main symptoms of depression. 
However, whereas in depression mood is low, mainly anticipatory anhedonia can be found in 
negative symptoms. Moreover, patients with schizophrenia (SCZ) show greater expressive 
deficits than those with Major Depressive Episode (MDE). We investigated if measures of 
depressive and negative symptoms differentiate SCZ subjects, subjects with MDE, and healthy 
controls (HC). 21 SCZ, 22 MDE, and 25 HC subjects were examined with a rater assessment and 
a self-rating for negative symptoms (Clinical Assessment Interview for Negative Symptoms 
(CAINS); Motivation and Pleasure – Self-Report (MAP-SR)) and depressive symptoms 
(Hamilton Rating Scale for Depression (HAMD-17); Beck Depression Inventory (BDI)). All 
measures differentiated the psychiatric samples from HC (all p’s < 0.01). The ratings of 
depressive symptoms (HAMD-17, BDI) and rater assessment of negative symptoms (CAINS) – 
specifically its sub scale measuring expressive deficits – managed to discriminate between subjects 
with schizophrenia and those with MDE (SCZ > MDE > HC for negative, MDE > SCZ > HC 
for depressive symptoms, all p’s < 0.05). The self-rating of negative symptoms (MAP-SR) did 
not. To differentiate negative symptoms and depression clinicians might look for (self-)reported 
low mood and observer-rated reduction in speech as well as in gestures and facial expression. 
Reduced expression and moderate levels of depression point towards a negative syndrome, 
whereas mostly unimpaired expression and high scores of self-reported depressive symptoms are 
more likely to indicate a depressive syndrome. 
 
1. Introduction 
1.1 Schizophrenia and Depression 
There is sound evidence pointing to a two-factorial structure of negative symptoms; the 
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first factor being “diminished expression” with blunted expression of emotions and poverty of 
speech and the second being “avolition” with amotivation, anhedonia and social withdrawal (e.g. 
Marder & Galderisi, 2017). Secondary negative symptoms are caused by positive symptoms, 
substance use, medication side effects and/or – particularly important here – depression (e.g. 
Kirschner, Aleman, & Kaiser, 2017). Negative and depressive symptoms can’t be differentiated 
easily, since there is considerable conceptual overlap. Mainly the avolition factor of negative 
symptoms encompasses symptoms that also belong to the main symptoms of depression: loss of 
interest, anhedonia, and reduced energy. 
Comorbidity rates are high for schizophrenia and unipolar depression across stage and 
state of illness (acute psychotic episode: up to 60% comorbid major depressive episode (MDE); 
post-psychotic: moderate to severe MDE in 20% of chronic patients and 50% of first-episode 
patients); there seem to be shared etiological aspects (Upthegrove, Marwaha, & Birchwood, 
2017). Longitudinally, up to 80% of patients with schizophrenia experience an episode of major 
depression (Upthegrove et al., 2010). Depression is the most important indicator for completed 
suicide in patients with schizophrenia (Dutta, Murray, Allardyce, Jones, & Boydell, 2011). Since 
both the treatment of depression in schizophrenia and of negative symptoms remains inadequate 
(e.g. Fusar-Poli et al., 2015; Lako et al., 2012), it seems of particular importance to reliably 
delineate negative and depressive symptoms. 
1.2. Expression, Mood and Subtypes of Anhedonia Might Differentiate Schizophrenia 
and Depression 
Emotional expression (i.e. speech, gestures and facial expressions) often is reduced in 
patients with schizophrenia compared to healthy controls and subjects with depression, which are 
nevertheless also showing expressional deficits (Berenbaum & Oltmanns, 1992; Gaebel & 
Wölwer, 2004; Riehle, Mehl, & Lincoln, 2018; Trémeau et al., 2005). Despite affective flattening, 
patients with schizophrenia often report unimpaired subjective experiences (e.g. Kring & Moran, 
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2008), whereas low, depressed mood is a main symptom of depression. Recent 
conceptualizations of anhedonia emphasize the importance of the (complex) reward system. Any 
reward system deficit (e.g. anticipatory or motivational anhedonia, disorganization) can hinder the 
individual from generating pleasurable experiences and could then present as (secondary) 
consummatory anhedonia (Lambert et al., 2018). There are findings indicating that patients with 
depression experience consummatory and anticipatory anhedonia whereas patients with 
schizophrenia mainly show a deficit in anticipatory pleasure (Gard, Kring, Gard, Horan, & 
Green, 2007; Lambert et al., 2018; Wu et al., 2017). The emergence of anticipatory pleasure is 
more complex than the experience of consummatory pleasure and hints at motivational deficits 
in schizophrenia as opposed to deficits in experiencing emotions (Foussias & Remington, 2010). 
1.3. Correlations of Rating Scales for Depression and Negative Symptoms 
Research on negative symptoms in the context of MDE seems scarce. Bottlender et al. 
(2003) found that negative symptoms (measured with the Scale for the Assessment of Negative 
Symptoms (SANS)) were significantly associated with depressive symptoms (measured with the 
Montgomery-Asberg Depression Rating Scale) in MDE patients but not in patients with 
schizophrenia. This could be due to the SANS’ item content that encompasses a lot of symptoms 
also germane to the depressive domain (e.g. affective nonresponsivity, poverty of content of 
speech, increased latency of response) and symptoms that are not thought to be specific for 
negative symptoms anymore, i.e. attention/cognitive symptoms (e.g. Marder & Galderisi, 2017). 
They found persisting negative symptoms to be indicative for schizophrenia and not MDE. 
For schizophrenia patients, Park et al. (2012) found a weak correlation between observer-
rated negative symptoms (CAINS) and the rater assessed Calgary Depression Scale for 
Schizophrenia (CDSS), Kring, Gur, Blanchard, Horan, and Reise (2013) found none. Engel, 
Fritzsche, and Lincoln (2014) reported no significant association of CAINS and self-assessed 
BDI-II. Llerena et al. (2013) found no significant correlation of self-rated negative symptoms 
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(MAP-SR) with the CDSS. Hartmann, Fritzsche, and Lincoln (2013) reported no significant 
correlation between the BDI-II and PANSS-rated negative symptoms (however, it should be 
noted that two of the seven PANSS negative items assesses cognitive symptoms (e.g. Marder & 
Galderisi, 2017)). However, Engel and Lincoln (2016) reported a moderate and significant 
correlation of the MAP-SR with the BDI-II (r = 0.39). Overall, we found some – if scarce – 
evidence for overlap when measuring the two symptom domains in patients with schizophrenia. 
Concerning self- vs. observer-ratings, Engel and Lincoln (2016) debated an underestimation of 
shared variance of negative and depressive symptoms when compared across sampling methods.  
1.4. Objectives 
We investigated if a) measures of negative symptoms and b) measures of depressive 
symptoms could differentiate between subjects with MDE, subjects with schizophrenia and 
healthy controls. We expect subjects with schizophrenia to show the greatest extent of negative 
symptoms and subjects with depression to show the greatest extent of depressive symptoms. 
Because of the overlap between negative symptoms and depression we expect subjects with 
schizophrenia to display more depressive symptoms and subjects with MDE to report more 
negative symptoms than healthy controls. We expect mainly the “expression” factor of negative 
symptoms and the assessments of depressive mood to reliably differentiate MDE and 
schizophrenia subjects. 
1.5 Selection of Instruments 
To assess the scope of negative symptoms we used the Clinical Assessment Interview for 
Negative Symptoms (CAINS, Engel et al. (2014)) and the self-rating instrument Motivation and 
Pleasure Scale – Self-Report (MAP-SR, Engel and Lincoln (2016)). The CAINS has been 
designed to assess negative symptoms according to the current conceptualization (Marder & 
Galderisi, 2017) and consists of two scales: “motivation and pleasure” (CAINS-MAP) and 
“expression” (CAINS-EXP). CAINS-EXP straightforwardly rater-assesses expressive deficits 
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with four items. CAINS-MAP focuses on aspects of inner experience with its authors arguing 
that this is central for the emotional, social and motivational deficits and to be distinguished from 
behavior or functional outcome (Kring et al., 2013). In the original validation study, the two 
factors correlate moderately (r = 0.24), show good internal consistency as well as test-retest 
reliability and interrater reliability. Convergent and discriminant validity (also to depressive 
symptoms) was established (Kring et al., 2013). A further validation study found good 
psychometric properties for the German CAINS as well, with high internal consistency, a 
moderate correlation between the two factors (r = 0.44), good inter-rater agreement as well as 
convergent and discriminant validity; the latter also with depression (Engel et al., 2014). The 
MAP-SR assesses the “avolition” factor of negative symptoms as a self-report and is based on the 
CAINS’ “motivation and pleasure” scale. It taps social pleasure, recreational or work pleasure, 
feelings and motivations about close, caring relationships as well as motivation and effort to 
engage in activities. Llerena et al. (2013) found good internal consistency as well as convergent 
validity with the CAINS-MAP (r = 0.65) and social anhedonia (r = 0.48). For social performance, 
there was no significant correlation. Discriminant validity was established (i.a. for 
depression/anxiety). For the German MAP-SR, Engel and Lincoln (2016) also found high 
internal consistency as well as mostly good convergent and discriminant validity. However, there 
was a moderate correlation with the BDI-II (r = 0.39). 
To assess the scope of depressive symptoms, we used the Beck Depression Inventory 
(BDI, Hautzinger (1991)) as self-rating and the Hamilton Depression Scale (HAMD-17, 
Hamilton (1967)) as rater assessment. Both tap emotional, cognitive, behavioral, and physical 
symptoms of depression. The BDI consists of 17 items and shows good validity, adequate test-
retest reliability, and good inner consistency (Beck, Steer, & Carbin, 1988). For the German BDI 
high internal consistency and good convergent validity is reported (Hautzinger, 1991). 
Concerning the observer rating, we expect greater discriminatory power from the HAMD’s 17-
item version as opposed to HAMD-21, since this version doesn’t assess paranoia and 
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depersonalization. The HAMD-17 is widely used and has good to adequate psychometric 
properties (e.g. Bagby, Ryder, Schuller, & Marshall, 2004). Because we expect items associated 
with mood to have the most discriminatory power, we researched established subscales with 
emphasis on mood for BDI and HAMD-17, respectively. The BDI subscale 
“cognitive/affective” consists of the first 14 items excluding somatic and functioning items (Beck 
et al., 1988). The Maier-Philipp Severity subscale of the HAMD-17 comprises the items assessing 
depressed mood, feelings of guilt, work and interests, retardation, agitation, and anxiety – psychic 
(Maier & Philipp, 1985). 
 
2. Methods 
2.1. Participants 
We included 21 participants with schizophrenia (SCZ), 22 participants with MDE and 25 
healthy controls (HC). The patients were recruited from in-patient settings. Inclusion criteria 
were diagnosis of a psychotic disorder (SCZ) or major depressive episode (MDE) or no diagnosis 
(HC) according to DSM-IV (assessed with the German Brief Diagnostic Interview of Mental 
Disorders (Mini-DIPS)), age 18 to 65 years, sufficient German language skills, normal or 
corrected to normal vision and hearing as well as capability to give consent. To avoid overlap 
between the psychiatric groups we did not include subjects with schizoaffective disorder or a 
MDE with psychotic symptoms. Since we wanted to measure present symptoms, we excluded 
patients in remission (i.e. only met “life time” criteria in the diagnostic interview). Further 
exclusion criteria were substance dependence as leading clinical problem and intellectual 
disability. To keep the sample structure comparable, we included healthy controls that 
corresponded in age and gender to the recruited SCZ patients. Since depressed patients skew 
older and female and we prioritized a representative sample, we refrained from doing that with 
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the MDE sample. Demographic and clinical characteristics of the samples can be found in table 
4-1. 
Table 4-1 
 
Notes. SCZ = participants with schizophrenia; MDE = participants with major depressive disorders; HC = healthy 
controls. 
2.2. Measures and procedure 
The study protocol was approved by the ethics committee of the University of 
Tuebingen’s medical faculty. After obtaining informed consent, screened participants who met 
inclusion criteria were interviewed and asked to fill in questionnaires (duration approx. 1.5 hours). 
Diagnosis was confirmed using the parts of the German Brief Diagnostic Interview of Mental 
Disorders (Mini-DIPS) that assess psychotic and affective disorders.  
The German translation of the CAINS was kindly made available to us by the research 
group led by Tania Lincoln, Department of Clinical Psychology and Psychotherapy, University of 
Hamburg. The English version of the MAP-SR was translated into German by our research 
group and retranslated by an English native speaker. Differences to the original English versions 
were discussed among the translators and a consensus was agreed on. 
2.3. Data analysis 
For demographic data a rate of missings < 10% was not reported. When calculating the 
self-ratings’ scale composites, a rate of 10% of missings was tolerated and replaced by the scale’s 
mean. Measures with more missing data were excluded from the analysis (one data point for 
Demographics
SCZ (n=21) MDE (n=22) HC (n=25)
Age (yrs) 35.10 (11.68) 42.36 (15.05) 34.28 (14.24)
Male (%) 86 50 68
Abitur (~A-level; %) 81 54 88
Age at 1st hospitalization (yrs) 23.71   (4.37) 35.36 (13.11) -
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MAP-SR and BDI, respectively). There were no missing data for the rater assessments. Scores for 
the MAP-SR were inverted so that larger scores indicate a greater extent of negative symptoms. 
With SPSS 25.0 we tested for normal distribution with the Shapiro-Wilk test. Since CAINS, 
MAP-SR, HAMD-17 and BDI and their subscales were all non-normally distributed in the 
control group, we used the non-parametrical Kruskal-Wallis-Test to assess the between-group 
effects. Post-hoc pairwise comparisons were performed using Dunn tests with Bonferroni 
correction.  
 
3. Results 
For the CAINS we found between-group differences in the scope of negative symptoms 
(H(2, N = 68) = 48.65, p < .001). Post-hoc analysis revealed significant differences between all 
groups: SCZ > MDE > HC, p < .05. MAP-SR also revealed differences between the groups 
(H(2, N = 68) = 25.77, p < .001). Here, post-hoc analysis showed SCZ = MDE > HC with p < 
.001 for MDE and controls and p = .007 for SCZ and controls. Because of the MAP-SR’s failure 
to differentiate SCZ and MDE, we further analyzed the CAINS’ two subscales and found that 
only its expression subscale significantly differentiated between subjects with depression and 
schizophrenia (SZC > MDE > HC). The group comparisons of the negative symptom scales can 
be found in figure 4-1. 
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Notes. Scores of MAP-SR inverted to reflect symptom load. * = p < 0.05, ** = p < 0.01, *** = p < 0.001.  
Figure 4-1. Group comparisons of CAINS and MAP-SR, and CAINS-MAP and CAINS-EXP; 
means with standard deviations and significance markers. 
 
Concerning the scope of depressive symptoms we found between-group differences for 
BDI (H(2, N = 67) = 41.83, p < .001). Post-hoc analysis showed that all three groups differed 
significantly from each other: MDE > SCZ > HC, p < .05. For HAMD-17, there were significant 
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differences as well (H(2, N = 68) = 54.14, p < .001). Post-hoc tests showed MDE > SCZ > HC, 
p < .05; see figure 4-2. 
 
Note. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
Figure 4-2. Group comparisons of HAMD-17 and BDI; means with standard deviations and 
significance markers. 
 
For the “mood associated” subscales of the measures for depressive symptoms, we found 
both to not significantly differentiate between depressed and schizophrenic subjects, while still 
showing between-group differences. HAMD-Maier-Philipp: H(2, N = 68) = 53.32, p < .001, 
MDE = SCZ > HC; BDI cognitive/affective: H(2, N = 67) = 37.12, p < .001, MDE = SCZ > 
HC. The “other” subscale of the HAMD17 as well as the somatic subscale of the BDI 
differentiated significantly between all groups. HAMD other: H(2, N = 68) = 43.74, p < .001, 
SZC > MDE > HC; BDI somatic H(2, N = 67) = 40.11, p < .001, MDE > SCZ > HC. The 
group comparisons of the depression measures’ subscales can be found in figure 4-3. 
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Note. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
Figure 4-3. Group comparisons of HAMD-17 Maier-Philipp and “other” subscales, and BDI 
cognitive/affective and somatic subscales; means with standard deviations and significance 
markers. 
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4. Discussion 
We investigated if subjects with schizophrenia, subjects with MDE, and healthy controls 
differ in the scope of their negative and depressive symptoms as measured by self-ratings (BDI, 
MAP-SR) and observer assessments (HAMD-17, CAINS). All measures differentiated the 
psychiatric samples from the controls. The full rating scales of depressive symptoms (HAMD-17, 
BDI) and the rater assessment of negative symptoms (CAINS) – and specifically the expressive 
deficits (CAINS-EXP) – managed to discriminate between subjects with schizophrenia and those 
with MDE reliably; the self-rating of negative symptoms (MAP-SR) did not. 
Concerning the CAINS, its “expression” subscale (CAINS-EXP, assessing vocal prosody, 
gestures, facial expression, and speech) significantly differentiates schizophrenic and depressed 
subjects whereas the “avolition” subscale does not (although its means also are SCZ > MDE > 
HC). This differentiating effect of the CAINS-EXP is consistent with previous evidence that 
shows reduced facial expression of subjects with schizophrenia compared to subjects with 
depression (which are nevertheless also showing diminished expression); this also holds true for 
involuntary facial activity (Berenbaum & Oltmanns, 1992; Gaebel & Wölwer, 1992; Trémeau et 
al., 2005). Gaebel and Wölwer (2004) found diminished expression beyond acute psychotic 
episodes in schizophrenia patients; in subjects with depression this was primarily found when 
acutely depressed. One explanation for the MAP-SR’s failure to distinguish the psychiatric groups 
could be poor self-assessment by subjects with schizophrenia. There is evidence for deficits in 
self-assessment, with mainly positive symptoms and cognitive symptoms negatively affecting the 
ability to self-assess correctly (Browne et al., 2000; Katschnig, 2000; Silberstein, Pinkham, Penn, 
& Harvey, 2018). However, Hartmann et al. (2013) assessed patients with psychosis for 
depression with two observer ratings (CDSS and PANSS) and two self-rating scales (BDI and 
Symptom-Checklist Revised (SCL-90-R)) and found self-ratings to correspond well with observer 
ratings. Since the CAINS “expression” subscale seems to play the decisive role, the MAP-SR’s 
failure to differentiate the psychiatric samples could be because it doesn’t measure expression. 
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Moreover, in contrast to the means of the CAINS “motivation and pleasure” sub-scale (SCZ > 
MDE > HC), MDE-subjects reported greater symptom load on the MAP-SR than subjects with 
schizophrenia (MDE > SCZ > HC). The MAP-SR doesn’t seem to measure symptoms in the 
“motivation and pleasure” domain that are specific for anhedonia/avolition in schizophrenia. Of 
its 15 items, six inquire past or expected pleasure, six motivation and effort concerning activities; 
there is clear overlap with depressive symptoms. The MAPS-SR as well as the CAINS-MAP 
might not assess enough items that are specific for this symptom domain (e.g. anticipatory vs. 
consummatory anhedonia, indifferent vs. depressed mood). Future research on instruments 
assessing the “amotivation” factor of negative symptoms might want to focus on the subtypes of 
anhedonia if the aim is to differentiate reliably from depression. Overall, the “expression” factor 
of negative symptoms seems to be specific and thus to date more relevant when differentiating 
MDE and negative symptoms of schizophrenia. Thus, a precise appraisal of negative symptoms 
should not only include inner experiences but also a nuanced assessment of expression. 
In this study, we used the BDI; the newer BDI-II additionally inquires agitation, 
worthlessness, loss of energy, and concentration difficulty and dropped body image change, work 
difficulty, weight loss, and somatic preoccupation. Interestingly, Hartmann et al. (2013) found 
that schizophrenia patients who self-reported fewer depressive symptoms than the clinicians 
observed, showed more negative symptoms, i.e. blunted affect and poor affective rapport. We 
also found slightly greater mean differences between schizophrenia patients and to MDE subjects 
in the self-assessment of depressive symptoms than in the observer rating. We supposed that 
while the HAMD-17 manages to differentiate patients with MDE and those with SCZ, there are 
some items that might reduce discriminatory power: four inquire physical symptoms, and three 
sleep problems. Patients with schizophrenia as well as clinically depressed patients both 
experience and report more physical symptoms (e.g. Greco, Eckert, & Kroenke, 2004; Leucht, 
Burkard, Henderson, Maj, & Sartorius, 2007). Particularly sexual dysfunction is a common side 
effect of antipsychotics (e.g. Baggaley, 2008). Moreover, 30 to 80% of schizophrenic patients also 
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suffer from sleep disturbances (Cohrs, 2008). Curiously, we could confirm this neither when 
analyzing the subscales of the HAMD-17 nor of the BDI. Focus on psychic symptoms and 
affective and cognitive symptoms of depression, respectively, did not increase discriminatory 
power. Conversely, the scales’ items that feature somatic and sleep symptoms seem to 
differentiate the psychiatric samples better. Maybe the subscales were still not specific enough for 
affective/mood symptoms. This warrants further research on the differential impact of the scales’ 
singular items. At this point, however, we propose utilizing the whole scales to help differentiate 
depressive from negative syndromes. 
4.1 Limitations 
Our psychiatric samples exhibited only mild to moderate negative and depressive 
symptoms respectively; a greater severity of symptoms might have shown the differences 
between the groups more clearly. Moreover, comparisons between SCZ and MDE groups are 
difficult since e.g. age of onset and gender ratio differ. However, a matching procedure would 
compromise representativity either of the schizophrenia or MDE sample. Furthermore, 
medication could be a confounding variable. Of the subjects with schizophrenia, 95% were on 
antipsychotic medication, 19% took at least one antidepressant. In the MDE group 31% of the 
subjects were on antipsychotics (usually in lower doses than the SCZ group), 91% on 
antidepressants. Medication-induced blunting could adversely affect the experience of pleasure in 
subjects with schizophrenia. These secondary negative symptoms could not be ruled out in the 
present study. Also, our raters were not blinded concerning the subject’s diagnosis – this could 
lead to over- or under-assessment of depressive and/or negative symptoms in concordance with 
diagnosis. 
4.2 Conclusion 
To differentiate negative symptoms and depression, clinicians might look for self-
reported depressive symptoms and observable reduction in expression. The self-report of 
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depressive symptoms is reliable and economical, but more importantly, there is evidence that the 
self-report might be more sensitive than rater-assessed depressive symptoms in schizophrenia 
patients (see also Hartmann et al., 2013). Reduced expression and moderate levels of depression 
point towards a negative syndrome, whereas relatively unimpaired expression and high scores of 
self-reported depressive symptoms are more likely to indicate a depressive syndrome. 
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The objective of this research project was to thoroughly assess two recently developed 
instruments measuring negative symptoms. To further research on negative symptoms, the 
construct needs to be measured with reliable instruments that reflect the two established factors 
diminished expression and amotivation structure- and content-wise. Thus, we comprehensively 
assessed the observer-rating CAINS with regard to the entire construct negative symptoms, the 
self-report MAP-SR for the subdomain amotivation, and both instruments for their ability to 
distinguish subjects with schizophrenia, subjects with depression and healthy controls. 
In this Chapter, a short general summary of all findings is given, followed by 1) thoughts 
on the temporal stability of negative symptoms, 2) a discussion of the factorial structure of 
negative symptoms in light of our results, 3) reflection on both scales’ construct validity with 
regard to a) our comprehensive validity assessment and b) their ability to differentiate negative 
and depressive symptoms, and 4) in closing, general conclusions on the instruments as well as 
clinical recommendations. 
 
1. General Summary of Findings 
For the Clinical Assessment Interview for Negative Symptoms, CFA found a two-
factorial structure with minor adjustments for the subscale measuring motivation and pleasure, 
confirming the two domains expressive deficits (subscale expression) and amotivation (subscale 
motivation and pleasure). The CAINS total score was strongly associated with negative 
symptoms measured by the PANSS as well as functional outcome. Discriminant validity was 
established with positive and extrapyramidal symptoms but not with cognitive deficits and 
depression. There were distinct profiles for the two subscales with regard to convergent and 
discriminant validity: CAINS-MAP was strongly associated with functional outcome and strong 
to moderately with PANSS Marder Negative and social cognition as well as depression, cognitive 
deficits, and positive symptoms. CAINS-EXP was not associated with sources of secondary 
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negative symptoms and cognitive deficits. There was good internal consistency and interrater 
agreement for both the CAINS and its subscales. Test-retest reliability was moderate for the 
CAINS total score and its expression subscale and low for the motivation and pleasure subscale. 
For the Motivation and Pleasure Scale – Self Report’s structure, one-, two- and three-
factor solutions were tested using exploratory factor analysis; they explained 36.18, 44.85, and 
50.93% of variance, respectively. Overall, we found one psychometrically robust factor, pleasure 
and hedonic activity, consisting of eight items. The other two factors – social motivation and motivation 
for work – are comprised of only two items each and all in all had less satisfactory psychometric 
properties. There was good internal consistency for the scale and all tested subscales. Our 
preliminary (n = 19, in-patients in the stabilization phase) test-retest reliability was adequate for 
the MAP-SR composite score and the subscale pleasure and hedonic activity, good for the 
subscale motivation for work, and poor for the subscale social motivation. The validity 
assessment found no significant correlations for the factor motivation for work; for the factor 
social motivation there were positive associations with social cognition as well as depression. 
Neither the MAP-SR nor the most promising factor, pleasure and hedonic activities, were 
associated with PANSS-measured negative symptoms or functional outcome. However, they 
were significantly and moderately related to the observer-rated CAINS-MAP, and strongly to 
experiences of pleasure and social cognition. With regard to discriminant validity, there were 
moderate associations with depression and extrapyramidal symptoms, but none with cognitive 
deficits and positive symptoms. 
When assessing the discriminatory power of the CAINS and MAP-SR as well as of the 
Hamilton Rating Scale for Depression and Beck Depression Inventory with regard to depressive 
and negative symptoms, all measures differentiated the patient samples (schizophrenia and major 
depressive episode) from healthy controls. Both ratings of depressive symptoms and the 
observer-rated CAINS – specifically its expression subscale – managed to discriminate between 
subjects with schizophrenia and subjects with MDE. As expected, patients with schizophrenia 
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showed more negative symptoms than patients with depression and controls; patients with MDE 
reported more depressive symptoms than patients with schizophrenia and controls. The MAP-SR 
ratings showed no significant difference in self-rated negative symptoms between patients with 
schizophrenia and those with MDE. 
 
2. Temporal Stability of Negative Symptoms 
As stated above, in this first evaluation of  the German CAINS’ test-retest reliability we 
found satisfactory temporal stability for the CAINS (r = 0.71) and its expression subscale (r = 
0.74) in a small sample of  19 patients and for a two-week interval. This was in line with the fairly 
good test-retest reliability scores reported in previous validation studies. However, the lower test-
retest reliability of  0.57 for the CAINS’ motivation and pleasure subscale and of  0.63 for the 
MAP-SR was surprising, considering the short interval between the assessments and the 
frequently reported (moderate) stability of negative symptoms (e.g. Ventura et al., 2015). Four 
other studies assessed the CAINS’ temporal stability, none those of the MAP-SR. For a two-week 
interval, Kring et al. (2013) report an r of  0.69 for both CAINS-EXP and CAINS-MAP (n = 
162); Xie et al. (2018) found an r of  0.63 for CAINS-EXP and 0.68 for CAINS-MAP (n = 23). 
For a one-month interval, Jung et al. (2016) report a test-retest reliability of  0.87 for CAINS-
EXP and 0.89 for CAINS-MAP (n = 98). Blanchard et al. (2017) analyzed a three-month interval 
with 447 subjects and found an r of  0.75 for CAINS-EXP and of  0.80 for CAINS-MAP. There 
were no obvious demographic differences between the patients assessed in those studies and our 
sample that could explain the lower temporal stability of the CAINS-MAP found in our data. 
However, there was a significantly higher rate of  out-patients in the other studies; our sample for 
the CAINS and the MAP-SR’s test-retest reliability assessment predominantly consists of  in-
patients in the stabilization phase. In this phase, depression, positive symptoms, and 
extrapyramidal symptoms might be more pronounced. We might thus have measured a greater 
percentage of  secondary negative symptoms that might be less stable than genuine negative 
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symptoms. The fact that we found the expression domain to be more independent from possible 
sources of  secondary negative symptoms than the amotivation domain strengthens this 
hypothesis. 
When comparing the CAINS with the BNSS, Strauss and Gold (2016) found remarkably 
higher test-retest reliability for the BNSS (0.88 for expression, 0.92 for motivation and pleasure) 
and point to differences in item content in the amotivation domain. In general, the CAINS-MAP 
and MAP-SR’s focus on inner experience (as opposed to the CAINS-EXP’s focus on observable 
behavior) might lead to a higher variability of  answers when retesting the amotivation domain, 
resulting in less reliable scoring. Furthermore, there is evidence that expressive deficits are more 
persistent while amotivation might be more sensitive to change (Galderisi, Mucci, et al., 2013; 
Kelley et al., 2008), but we doubt this holds true for our two-week interval.  
Overall, the temporal stability of  the different aspects of  negative symptoms still seems 
to be insufficiently studied. A major difficulty may be the heterogeneity of  the symptom 
complex; this is still not fully reflected in the measurement instruments. The two domains and 
five subdomains of  negative symptoms might well be affected differently by sources and types of  
negative symptoms as well as phase of  illness. Negative symptoms of  the deficit syndrome, 
persistent negative symptoms, primary, and secondary negative symptoms quite possibly differ in 
their susceptibility for change. Based on our results and with regard to test-retest reliability, it 
seems that the amotivation domain might benefit most from further studies. This could be a 
comparison of  the temporal stability of  its components anhedonia, avolition and social 
withdrawal while controlling for secondary negative symptoms. As well, the test-retest reliability 
of  negative symptoms for the same interval but in different phases of  illness (e.g. prodromal, 
acute, and residual) could be looked into. 
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3. Deconstructing Negative Symptoms 
3.1. Confirmatory Factor Analysis of the CAINS 
When conceiving this research project, a two-factorial structure of the CAINS had just 
been identified with exploratory factor analysis in the original validation study (Kring et al. 
(2013); n =162) as well as for the German (Engel et al. (2014); n = 53) and the Spanish version 
(Valiente-Gomez et al. (2015); n = 100). As of yet, there are three further confirmatory factorial 
analyses. In a sample of 119 Korean subjects, Jung et al. (2016) report a confirmation of the two-
factorial structure with CAINS-MAP and CAINS-EXP, however, their goodness of fit statistics 
were not in an acceptable range (TLI = 0.806, CFI = 0.863, RMSEA = 0.140). Like us, Xie et al. 
(2018) had to modify their initial model to account for shared variance of some items but 
confirmed the overall two-factorial structure for the Chinese CAINS with good fit indices 
(RMSEA = 0.053, NNFI = 0.99,CFI = 0.99, AIC = 155.02; n = 185). In Singapore, Rekhi et al. 
(2019) found no acceptable fit for the initial two-factorial structure (RMSEA = 0.133, CFI = 
0.869, TLI = 0.840, WRMR = 1.750). Exploratory factor analysis of a split-half sample (n = 133) 
found four factors: motivation and pleasure social, motivation and pleasure vocational, motivation and pleasure 
recreational, and expression. CFA confirmed this structure for the second split-half sample (n = 141) 
and with acceptable fit statistics (RMSEA = 0.078, CFI = 0.955, TLI = 0.940, WRMR = 0.793). 
Looking further, there is a recent comprehensive factor-analysis on the Brief Negative Symptom 
Scale that found the best fit for a hierarchical five-factor model with two second-order factors 
expression and motivation and pleasure as well as five first-order factors blunted affect, alogia, 
anhedonia, avolition, and asociality (Ahmed et al., 2018). 
When planning this CAINS validation, we judged that the two-factorial structure of the 
CAINS (that was overwhelmingly found in previous exploratory analyses) could be responsibly 
confirmed using our approach. Our sample size of 105 is sufficient: Jackson, Voth, and Frey 
(2013) propose to take p/f ratios (i.e. number of measured variables loading on each factor), 
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number of latent variables and loading size into account when planning sample size. Their 
guidelines suggest that for our two factors, a p/f of four and nine and expected loading sizes 
between .4 and .9, a sample size of 50 to 100 can be sufficient. Moreover, CFAs with about 100 
cases can be routinely found in literature. We further chose to include the goodness-of-fit 
statistics Root Mean Square Error of Approximation (RMSEA) and Comparative Fit Index (CFI) 
that are considered to be less sensitive to sample size compared to other indices (Fan, 
Thompson, & Wang, 1999). Since this is a smaller sample, we could not compare different 
factorial models. Further studies absolutely should explore the above-mentioned hierarchical five-
factor structure for the CAINS. For their comprehensive analysis of the BNSS’s structure, 
Ahmed et al. (2018) prepended exploratory factor analysis (n = 566) before comparing different 
models with CFA in five cross-cultural samples (China: n = 163, Italy: n = 371, Spain: n = 115, 
Switzerland: n = 119, and USA: n = 357). This is in line with i.a. Brown and Moore (2012)’s 
recommendation: “Unlike EFA, CFA requires a strong empirical or conceptual foundation to 
guide the specification and evaluation of the factor model. Accordingly, EFA is often used early 
in the process of scale development and construct validation, whereas CFA is used in the later 
phases when the underlying structure has been established on prior empirical and theoretical 
grounds” (p. 361). Thus, while we believe our results are sound with regard to the overlying two-
factorial structure, we think that for the CAINS, the hierarchical five-factor solution should first 
be looked at with EFA and then subsequently CFA. This is beyond the scope of this study. 
This confirmatory factor analysis remains the first CFA of the CAINS on a western 
sample. We consider the final model an overall well fitting and parsimonious model. All items 
were specific for their respective scales, since we found no cross-loadings of  CAINS-MAP items 
to the CAINS-EXP subscale and vice versa. The loadings of  the three CAINS-EXP items on the 
expression subscale are both high and reliable. However, for CAINS-MAP we found slightly less 
straightforward results that could indicate that the amotivation subdomains’ latent structure may 
still not be fully clear. For the CAINS-MAP items 1 (motivation for familial relationships), 5 
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(motivation for work and/or school) and 6 (expectation of  pleasure at work and/or school) the 
lower bound of  the item loadings’ confidence intervals is below 0.3, thus they are not as closely 
associated with their domain. Those three items were also in the bottom four of  factor loadings 
of  the original validation study’s exploratory factor analysis (Kring et al., 2013). When 
considering the item contents, overlap between some CAINS-MAP items was to be expected. We 
accounted for the following relevant overlap in our final model: 1) items 5 and 6 measuring a) 
motivation for and b) expectation of  pleasure at work and/or school, 2) items 3 and 4 tapping a) 
past-week and b) expected pleasure concerning social activities, and 3) items 4 and 9 assessing 
expected pleasure in regard to a) social activities and b) leisure activities. In their CFA, Xie et al. 
(2018) also report shared variance for those three and five further item pairs. To further clarify 
the relevance and validity of  the individual items of  the CAINS-MAP, further research could 
focus on identifying subclusters and respective item loadings in that domain, again looking to 
Ahmed et al. (2018)’s hierarchical five-factor model.  
At a more fundamental level, the two-factorial structure could be explained by common-
method variance: CAINS-MAP focuses on verbal report of  experience; CAINS-EXP relies on 
ratings of  within-interview behavior. This fundamental difference in assessment of the two 
domains is hard to resolve. Experience sampling is paramount for a full picture of amotivation, 
while self-assessment of expressive deficits has proven difficult so far. Park et al. (2012) found 
poor psychometric properties for the expression subscale of the first version of a CAINS-based 
self-report. Dollfus et al. (2016) also had problems in clearly differentiating amotivation and 
expression in their SANS-derived self-assessment. However, when taking into account the results 
of the validity assessment that found distinct correlational profiles for the subscales across 
measurement methods, it seems fair to assume that common-method variance only explains part 
of the differences between the factors. 
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3.2 Scale Construction of the MAP-SR 
To our knowledge, there still is no other inquiry into the MAP-SR’s factorial structure. 
The sample size of 93 met the methodological requirements for the exploratory factor analysis. 
As Stevens (2002) suggests 0.57 and 0.51 as critical values for relevant factor loadings in sample 
sizes of 80 and 100, respectively, we considered loadings ≥ 0.55 adequately reliable. Regardless of 
sample size, Guadagnoli and Velicer (1988) consider factors with four or more loadings greater 
than 0.6 reliable. We decided to explore a one-, two-, and three-factor-solution. The MAP-SR 
initially was constructed to measure one factor, i.e. the amotivation factor of negative symptoms. 
The 1976 version of Verlicers’ Minimum-Average-Partial-Test also suggested one factor for 
extraction. Its 2000 version proposed three factors; Ahmed et al. (2018)’s hierarchical model of 
negative symptoms measured with the BNSS also found three first-order factors for the second-
order factor amotivation. With a look to the scree plot, a two-factor solution also seemed fit for 
consideration. 
Of the 15 MAP-SR items, six are designed to assess pleasure. For them, we found reliable 
factor loadings on the factor pleasure and hedonic activities in the one-, two- and three-factor 
models. Additionally, they mostly show adequate test-retest reliability as well as convergent 
validity with corresponding CAINS items. The nine items assessing motivation were more 
problematic: In all factor models, two items had relevant loadings on the factor pleasure and 
hedonic activities but where not temporally stable and did not correlate with corresponding 
CAINS items or constructs. Those two items inquire motivation for hobbies, ergo hedonic 
activities that are closely related to the pleasure construct. For the two- and three-factor-models, 
the two items tapping motivation for social activities load on a common factor - social 
motivation – but had no satisfactory stability or convergent validity. In the three-factor model, 
two items inquiring motivation for work make up the factor motivation work and showed good 
convergent validity with CAINS items and constructs as well as sufficient temporal stability. 
Three items (7, 8 and 9) do not load reliably on any of the factors in any of the factor solutions 
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(but have their highest loadings on factor one). Moreover, item 9 (importance of friendships) 
does not converge with the corresponding CAINS item, item 7 (importance of family relations) is 
not stable over time, and item 8 (importance of romantic relationships) has a lot of missing data, 
probably because it is difficult to answer for single subjects. 
The MAP-SR set out to provide a valid self-report of the amotivation domain of negative 
symptoms. Unfortunately, we think structure-wise the MAP-SR is not yet sufficiently developed. 
While we found one robust, promising factor in all inquiries, this factor – pleasure and hedonic 
activities – only consists of eight of the 15 items and mainly seems to encompass anhedonia. For 
the two further factors, motivation for work could correspond to the subdomain avolition, and 
social motivation to social withdrawal, but both only consist of two items. We propose to use 
items 1 to 6 and item 14 and 15 as a “pleasure and hedonic activity” scale covering the anhedonia 
subdomain of the amotivation domain and recommend reconstruction of the motivation part of 
the questionnaire. This means including new and more items covering different aspects of 
motivation. Motivation for social relations (i.e. social withdrawal) and drive for activities (i.e. 
avolition) could be surveyed more in detail and might benefit from more straightforward 
questions. The CAINS’ and the BNSS’ related items and their probe questions could provide 
guidance. Amount and intensity of contact, who initiated, feelings of closeness and desire for 
contact could be additionally inquired with regard to sociability. The amount of time spent doing 
something vs doing nothing, personal initiative and perseverance could be tapped for avolition. 
The resulting scale would have to prove itself in further validation studies, but might be a more 
valid self-assessment of the whole amotivation domain.  
3.3 Conclusion on the Structure of Negative Symptoms 
While our findings robustly confirm an overlaying two-factorial structure for the CAINS, 
the results for the motivation and pleasure subscale of the CAINS and for the MAP-SR suggest 
that the complexity of the latent structure of negative symptoms might not be sufficiently 
CHAPTER 5: GENERAL DISCUSSION 
 
115 
reflected in the two proposed factors amotivation and expression. This is consistent with the 
findings of Xie et al. (2018) who also had to account for item overlap in the amotivation domain 
in their final model, those of Rekhi et al. (2019) who could not confirm the two factors and 
found four subscales in the social, vocational, recreational and expression domain, and, finally, 
Ahmed et al. (2018)’s findings on the structure of the BNSS. In a recent oral session and 
presumably presenting some not yet published findings, Ahmed et al. (2019) reiterated their 
support for a re-conceptualization of the latent structure of negative symptoms with a focus on 
the five consensus domains. They report that a structure with two second-order factors, 
expression and amotivation, and five first-order factors, blunted affect, alogia, anhedonia, 
avolition, and asociality, was found for different observer-rated assessment scales, across cultures, 
and using different statistical approaches. This should be inquired for the CAINS in further, 
larger studies. The hierarchical five-factor model could also inform the proposed redesign of the 
MAP-SR. 
 
4. Inner Experience and Observed Behavior 
With regard to their content, both CAINS and MAP-SR aim to put a greater focus on the 
patient’s inner experience. However, in order to assess the negative symptom complex 
comprehensively, it seems that some symptoms still need to be observer-rated. In the following, 
the construct validity of the CAINS and MAP-SR is reviewed and discussed with regard to our 
multi-method approach and across diagnoses. 
4.1 Validity Assessment of the CAINS 
We found distinct correlational profiles for the two subscales CAINS-MAP and 
CAINDS-EXP; this again substantiates the claim that they measure different aspects of negative 
symptoms. The motivation and pleasure scale has more positive associations with related 
domains than the expression subscale, which in turn is not significantly associated with sources 
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of  secondary negative symptoms. Both subscales correlate well with the PANSS Marder Negative 
score and moderately (CAINS-EXP) to strongly (CAINS-MAP) with deficits in social 
competence assessed with role-play. According to Marder and Galderisi (2017) abnormal 
functioning of  the mirror neuron system could lead to deficits of  social perception and motor 
activity which in turn affect social competence and expressive deficits. Additionally, it is highly 
likely for assessments derived from behavioral observation – i.e. CAINS-EXP items and 
assessment of  role-play – to overlap because of  common-method variance. For the amotivation 
domain, poor social cognition seems associated with social withdrawal (e.g. Marder & Galderisi, 
2017). Blanchard, Park, Catalano, and Bennett (2015) also found strong associations of  
amotivation symptoms and role-plays; they suspect an influence of  social amotivation on social 
competence. As expected from previous research (Gard et al., 2007), anticipatory anhedonia was 
associated specifically with the CAINS-MAP. Functional outcome consistently is linked more 
strongly to amotivation than expressive deficits (Marder & Galderisi, 2017); this is also found in 
our results. However, the correlation of  the CAINS-MAP and the very meticulously measured 
level of  activity was smaller than initially expected. This probably is due to the CAINS-MAP’s 
focus on inner experience as opposed to behavior. Since behavior can be confound with 
functional outcome, this smaller than expected association with the activity level could indicate a 
strength of  the CAINS-MAP. 
Looking at discriminant validity, the CAINS’ validity sample consisted of  70 outpatients 
with relevant but overall moderate negative symptoms and excluded severely depressed patients. 
There was a very low rate of  extrapyramidal symptoms. The subjects often were assessed shortly 
after leaving the hospital; a phase of  illness associated with less positive and more depressive 
symptoms (Peralta et al., 2000). We found a weak link of  the motivation and pleasure subscale 
with positive and depressive symptoms. There is conceptual overlap of mainly the amotivation 
domain and depression with loss of interest, anhedonia, and reduced energy featuring in both. 
This association of the amotivation subdomain and depression was not found in most other 
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validation studies (Engel et al., 2014; Jung et al., 2016; Kring et al., 2013; Rekhi et al., 2019) 
except by Valiente-Gomez et al. (2015). However, looking to our further results when trying to 
differentiate patients with schizophrenia and patients with depression, we consider the 
delineation of amotivation and depression non-trivial. Finally, common-method variance could 
play a part in the overlap of  mainly amotivation and positive as well as depressive symptoms. 
The global index of  cognitive deficits was moderately correlated with the CAINS-MAP. 
Amotivation is linked to deficits in abstraction and flexibility, and executive functioning which in 
turn could impair action planning resulting in apathy (Marder & Galderisi, 2017). Low cognitive 
effort is associated with more severe negative symptoms and both predict global neurocognitive 
impairment (Strauss, Morra, Sullivan, & Gold, 2015). In our data, there was no association of  
expressive and cognitive deficits, even though diminished expression often is linked with 
impaired overall cognitive performance (Hartmann-Riemer et al., 2015). There is evidence for 
specific pathways of  subdomains of  negative symptoms and particular cognitive deficits (A. S. 
Cohen, Mitchell, & Elvevåg, 2014). This is beyond the scope of  this research project, as our 
neurocognitive index is too unspecific to shed light on these complex associations. 
In validating the CAINS, we employed a wide range of measuring instruments; our results 
point to a predominantly good convergent and discriminant validity. For some associations, there 
is justified concern with regard to common-method variance. The systematic employment of self-
reports, caregiver reports, experience sampling and observer-rating for all domains in further 
studies could clear up this issue. 
4.2 Validity Assessment of the MAP-SR 
There sometimes is doubt whether patients with psychosis are able to adequately self-
assess their symptoms. There is some evidence that positive symptoms and cognitive symptoms 
negatively affect the patients’ ability to do so (Browne et al., 2000; Katschnig, 2000; Silberstein, 
Pinkham, Penn, & Harvey, 2018). However, Hamera, Schneider, Potocky, and Casebeer (1996) 
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found incongruence of self-report and rater assessment for negative symptoms and higher 
congruence for positive and other non-psychotic symptoms; however, the negative symptoms 
were only assessed with two items (emotional withdrawal and motor retardation). In contrast, 
Liraud, Droulout, Parrot, and Verdoux (2004) found satisfactory self-assessment for positive and 
negative symptoms (except for persecutory delusion and alogia). There are some findings 
contrasting self-reports and clinician-assessments specifically for the negative symptom domain: 
Bowie et al. (2007) found that patients underestimating their functional status show better 
cognitive performance and report more depressive symptoms than overestimators. Accurate 
raters had better social skills than both other groups. Overestimators were most cognitively and 
functionally impaired. Over-/underestimation may be moderated by factors like depression, 
positive symptoms, cognitive functioning, and insight and could play a role when reporting or 
observing negative symptoms. For patients and psychiatrists assessing negative symptoms, Selten, 
Wiersma, and van den Bosch (2000) found discrepancy between the assessments to be impacted 
negatively by depression, positively by anxiety, and found no impact of insight. All in all, there is 
insufficient evidence to disregard self-assessment in psychosis in general. 
There are significant associations of both the MAP-SR and the pleasure and hedonic 
activities factor with the observer-rated CAINS-MAP, a questionnaire sampling experiences of 
pleasure, and social cognition, but none with the PANSS Negative Scale and functional outcome. 
Thus, the MAP-SR indeed measures some aspects of negative symptoms. The criticism of the 
PANSS Negative Scale stated in chapter 1 (focused on observable behavior, includes items not 
considered part of the negative symptom domain) could partly explain the lack of correlation of 
MAP-SR and PANSS Negative Scale. They may well represent opposite ends of the spectrum of 
negative symptoms: one focused on subjective experience, the other closer to functional 
outcome. Thus, the MAP-SR might tap aspects of the negative symptom domain which might 
not be picked up reliably by observer ratings, e.g. inner need for company/engagement/activities 
vs. mere attendance, experienced pleasure vs. observed expression of emotion. A limitation of 
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the validity results is some possible common-method bias, since mainly other self-rating 
instruments correlate highly. 
For the discriminant validity assessment, there were difficulties with regard to depression 
and extrapyramidal symptoms. The MAP-SR’s validity sample comprised 55 outpatients with 
relevant negative symptoms, but with depressive symptoms below severe. The very low rate of and 
thus low variance in extrapyramidal symptoms could explain their correlation with both the 
MAP-SR and the pleasure and hedonic activity factor. The association of depression with the 
MAP-SR, the pleasure and hedonic activity factor, and the social motivation factor is quite 
probably due to the above-mentioned overlap of the amotivation domain and depression. Engel 
and Lincoln (2016) found significant correlations of the MAP-SR and self-rated depression as 
well. Of the MAP-SR’s 15 items, six inquire past or expected pleasure, six motivation and effort 
concerning activities; this probably is not specific for negative symptoms. This delineation from 
depression seems to be another relevant limitation of the MAP-SR, as can further be seen in the 
next section. 
4.3 Differentiating Negative Symptoms and Depression 
As already mentioned in the general summary of findings, the observer-rating and the 
self-rating for depressive symptoms managed to differentiate subjects with depression, subjects 
with schizophrenia and healthy controls. Further, both the CAINS and the MAP-SR were able to 
separate the control sample from the psychiatric samples. For the CAINS, the expression 
subscale significantly differentiates schizophrenia and MDE subjects whereas the amotivation 
subscale does not. This is consistent with the result of our validation study, that also found 
overlap of CAINS-MAP but not CAINS-EXP with depression. The differentiating effect of the 
CAINS-EXP also is in line with evidence for reduced facial expression of patients with 
schizophrenia as opposed to subjects with depression (Berenbaum & Oltmanns, 1992; Gaebel & 
Wölwer, 1992; Trémeau et al., 2005). 
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One explanation for the MAP-SR’s failure to distinguish the psychiatric groups could be 
poor self-assessment by subjects with schizophrenia. However, Hartmann et al. (2013) found 
good correspondence of self-ratings and observer ratings in patients with psychosis for two 
observer ratings (Calgary Depression Scale for Schizophrenia (CDSS) and PANSS) and two self-
rating scales (BDI and Symptom-Checklist Revised (SCL-90-R)). Since the CAINS expression 
subscale seems decisive when differentiating the psychiatric samples, the MAP-SR’s failure to do 
so could be because it doesn’t measure expression. However, on the MAP-SR, MDE-subjects 
reported even greater symptom load than subjects with schizophrenia; this was in contrast to the 
means of the CAINS-MAP (schizophrenia > MDE > controls). Thus, the MAP-SR and – to a 
lesser extent – the CAINS-MAP don’t seem to measure symptoms in the amotivation domain 
that are specific for schizophrenia. If the aim is to differentiate negative symptoms reliably from 
depressive symptoms, future research on instruments assessing the amotivation domain might 
profit from focusing on subtypes of anhedonia, e.g. anticipatory vs. consummatory anhedonia 
and indifferent vs. depressed mood. 
The psychiatric samples exhibited mild to moderate negative and depressive symptoms, 
respectively; a greater severity of symptoms might have sharpened the differences between those 
groups. Moreover, for the sample of patients with schizophrenia and the sample with MDE, i.a. 
age of onset and gender ratios differ. However, matching would have compromised the 
representativity of either the schizophrenia or the MDE sample. Furthermore, medication could 
be a confounding variable: Of the subjects with schizophrenia, 95% were on antipsychotic 
medication, 19% took at least one antidepressant. In the MDE group 31% of the subjects were 
on antipsychotics (mostly in lower doses than the patients with schizophrenia), 91% on 
antidepressants. Lastly, our raters were not blinded with regard to the subjects’ diagnoses – this 
could lead to over- or under-assessment in concordance with diagnosis. 
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4.4 Conclusions on Construct Validity 
Overall, the assessment of  expressive deficits is straightforward and observation-focused 
for the CAINS-EXP, resulting in a distinct profile with a particular strength concerning the 
disassociation from related concepts (i.e. sources of  negative symptoms, particularly depression). 
Whether a reliable self-rating of  this domain can be achieved remains unanswered. 
CAINS-MAP and MAP-SR focus on inner experience which is harder to pinpoint; this 
might be the reason for the less clear-cut correlational profiles. However, while the CAINS-MAP 
seems to measure a great extent of  the amotivation domain and hints at specificity with regard to 
depression, the MAP-SR seems to have difficulties here. Nevertheless, a focus on experience 
sampling as opposed to predominantly behavior-based assessments seems essential to prevent 
confounding symptoms and outcome – a problem of  the older generation measuring 
instruments. 
Neither the CAINS nor the MAP-SR entirely solve the problem of  distinguishing primary 
and secondary negative symptoms. Assessing true amotivation, and to an extent also true expressive 
deficits, will probably remain difficult. Assessment from more than one perspective (i.e. 
performance assessments, experience sampling, and self-reports complemented by caregiver 
reports) could help in this regard. 
 
5. General Conclusions and Clinical Recommendations 
To tackle the clinical challenge presented by the negative symptom complex, we need to 
understand it well, develop specific treatments, and precisely assess these interventions. The 
CAINS is overall well suited to promote these purposes, and we particularly recommend taking 
into account both CAINS subscales separately. Overall, the two subscales clearly and mostly 
reliably measure distinct aspects of  negative symptoms. These different aspects, however, should 
be further investigated with particular attention to the five consensus subdomains (blunted affect, 
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alogia, anhedonia, avolition, social withdrawal) in order to further refine the two-factorial 
structure found so far. This could also help clarify the CAINS-MAP individual items’ specific 
subdomains, and thus their importance for the subscale. 
It can be argued that self-assessments have been a blind spot for quite some time in the 
assessment of psychotic symptoms. There are well-known rater biases in clinical assessments (e.g. 
Hoyt, 2000), and particularly in patients with difficulties expressing emotions, self-reports could 
reflect the inner experience of patients more validly. However, while the MAP-SR is adequate to 
assess anhedonia (although not specifically for negative symptoms), it is less suitable when 
assessing motivation and features no expression subscale. We think the increasing focus on the 
subjective experience of symptoms with regard to i.a. treatment outcome intensifies the need for 
valid and reliable self-rating instruments and there should be increased efforts to improve existing 
or develop new self-reports. 
Since there is non-trivial conceptual overlap between the negative symptoms and 
depression, and since depression is the most important indicator for completed suicide in patients 
with schizophrenia, it seems of particular importance to reliably differentiate negative and 
depressive symptoms. To do so, clinicians should look for self-reported depressive symptoms 
and observable expressive deficits. Reduced expression and moderate levels of depression point 
to a negative syndrome, whereas relatively unimpaired expression and high scores of self-
reported depressive symptoms are more likely to indicate a depressive syndrome. 
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